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In the weeks before the initial publication of ACORN, we met 
with William B. Gartner, the Spiro Professor of Entrepreneurial 
Leadership at Clemson University and the founder of ACORN to 





Tell me a story about the startup of ACORN.
William Gartner
Well, first of all, ACORN is an ongoing effort of the 
Spiro Institute for Entrepreneurial Leadership to publish 
interviews of entrepreneurs telling their stories about 
the creation of their businesses.  I think there are many 
important insights into the process of entrepreneurship that 
can be gained by studying what entrepreneurs say about 
their entrepreneurial efforts.  Not only do these interviews 
offer insights into the specific activities of how ventures are 
created, they also demonstrate some of the thought processes 
involved in venture creation in addition to providing 
important lessons for others who want to develop their own 
businesses.  
ACORN is one of a number of projects supported by the 
Spiro Institute for Entrepreneurial Leadership focusing on 
“entrepreneurial narrative.”  From an academic perspective, 
the stories that entrepreneurs tell about their business 
creation efforts (which is one aspect of entrepreneurial 
narrative) can be analyzed in a variety of ways to understand 
how individuals take ideas and transform them into 
businesses.  An academic label for what entrepreneurs talk 
about is a “rhetoric of the future.” By “rhetoric of the future,” 
I refer to how entrepreneurs talk about how things will come 
into existence even when, for example in the interviews that 
follow, they are asked about the past. Entrepreneurship is 
forward thinking, so entrepreneurs’ talk is forward oriented 
as well.  What I have proposed that academic scholars do 
as a way to study these stories is to develop a “science of the 
imagination.”  Entrepreneurs create the future by “seeing the 
future in their heads” and then working to take what they 
4 ACORN
see (however clear or fuzzy these images are) and turn them 
into real things.  So, we need to systematically study how the 
entrepreneurial imagination works, and one of the best ways 
to do this is to study what they say about how they started 
their businesses.
This first issue is a collection of interviews of entrepreneurs 
who have started businesses based around new technologies 
at Clemson University.  We have sought out a variety 
of entrepreneurs who started businesses many years 
ago (e.g., Dee Cross: Equitox and Jack Peck: Fox Fire, 
both entrepreneurs were faculty members at Clemson), 
entrepreneurs with very recent startup efforts (e.g., Matt 
Geavart: Kiyatec and Elizabeth Cates: Inveca),  ventures 
started by an entrepreneur using Clemson technologies 
(Michael Bollick: Selah Technologies) and blends of 
Clemson faculty and entrepreneurs involved in venture 
startups (Earl Wagener, John Ballato, and Steven Foulger: 
Tetramer and Chuck Pringle, Andrew Clark, and Brent 
Buckner: SensorTech).   These interviews are by no means 
a comprehensive list of all of the startups that have been 
generated because of new technologies and entrepreneurial 
efforts at Clemson University.  What the interviews in 
this issue reflect is a change in the overall mindset of 
the University to a more entrepreneurial view of how 
Clemson University can foster significant economic and 
technological changes that have large impacts on South 
Carolina, the United States, and the world.  There is a lot 
of entrepreneurial activity at Clemson University, and these 
interviews reflect a part of that.
Now, as to how ACORN came into being:  I actually had 
the idea for something similar to ACORN when I began my 
academic career at the University of Virginia in 1981.  My 
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initial research involved detailed interviews of entrepreneurs, 
and I was struck with how much information these 
interviews contained about the process of entrepreneurship.   
While I was an assistant professor at the University of 
Virginia, I took a number of courses in magazine and book 
publishing, and I even wrote a business plan on the idea of a 
business publishing entrepreneurial interviews; however, for 
me, the time was not ripe for actually pursuing the idea.  An 
academic career involves a significant amount of scholarly 
research that results in academic journal articles, so while the 
idea seemed intriguing, I needed to focus on my scholarly 
work in order to continue as an academic and climb the 
ladder from assistant to associate to full professor.  Maybe if I 
had been able to “multi-task,” I could have accomplished my 
scholarly activities and pursue this interview idea, but I guess 
for me my scholarly efforts required my full-time attention 
for a lot of years.
It was not until I came to Clemson University in 2004 
that the idea of publishing interviews of entrepreneurs 
became feasible.  And, the feasibility of the idea came about 
for a number of reasons.  First, I had launched a major 
international academic effort to explore entrepreneurial 
narratives as a legitimate scholarly activity.  So, I could 
see that any efforts I put into this area could also be seen 
as having some scholarly legitimacy as I moved forward.  
This aspect should not be under-estimated.  In a scholarly 
institution like Clemson, you have to do scholarly things.  It 
is how the game is played.  Second, I had a lot of support 
from the then Dean of the College of Business and 
Behavior Science at Clemson University, Bruce Yandel, who 
encouraged me to dream about what I wanted to see happen 
in entrepreneurial leadership at Clemson. He then helped 
raise money and open doors for me in the community to 
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make it so.  Caron St. John, Director of the Spiro Institute, 
also played a major role in supporting me by give me a lot of 
freedom in my role as the Spiro Professor of Entrepreneurial 
Leadership to try out new things.
By January 2007, the resources necessary to start ACORN 
began to fall into place.  Bruce and Caron had contacted the 
Hollingsworth Foundation on my behalf, and after writing a 
proposal to the Foundation, we were awarded a grant to pay 
for the costs of interviewing entrepreneurs and publishing 
edited transcriptions of these interviews. Around the same 
time, Provost Dori Helms had initiated a university-wide 
program, “Creative Inquiry,” that provided opportunities 
for students to work with professors on research projects.  
For me, this meant I could sponsor a small class of students 
who could earn academic credit to interview entrepreneurs 
and engage in analyses of these entrepreneurs’ stories.  I was 
very lucky that two of my best students from a Sociology 
class that I taught on entrepreneurship were willing to work 
with me for two semesters to interview entrepreneurs in 
South Carolina.  As one will see in reading these interviews, 
these two students (who have now graduated from Clemson 
University) are Elana Shorb and Judith Campbell.  Their 
names are listed as the editors of the interviews for which 
they were responsible.
Our initial interview efforts focused more broadly on 
technology-oriented startups in South Carolina.  It was 
after we had conducted a dozen or so interviews that we 
realized that the initial issue of ACORN should focus 
on entrepreneurs with a Clemson University technology 
connection.  There is strong interest nationally among 
scholars and policy makers regarding the role of universities 
in technology commercialization.  I think these interviews 
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add to this discussion by portraying the critical role of 
entrepreneurship in commercializing technologies. So, over 
the past two years I have worked with a number of students 
in my Creative Inquiry course (entitled: Entrepreneurial 
Narrative) to interview entrepreneurs about their business 
startups.
Now, while one part of the equation was solved by 
interviewing entrepreneurs, another critical aspect of 
developing ACORN needed to be solved: actually publishing 
the interviews.  A lot of work has been undertaken in order 
for ACORN to be published in the form you see here.  For 
example, transcriptions of the interviews needed to be fine 
tuned (which meant working with the entrepreneurs on their 
transcription revisions until they were satisfied with their 
stories), a layout design for ACORN needed to be created, 
interviews had to put into this layout format (as you see 
here), photographs of the entrepreneurs needed to be taken, 
a printer needed to be found, the work to print ACORN 
needed to be coordinated, and ACORN had to be put on 
the Spiro Institute website, as well.  A thousand different 
details that, frankly, I am not talented or skilled enough 
to carry out. All of these critical tasks were undertaken 
by Ali Ferguson, who became involved with this project 
in July, 2009.  Ali graduated from the Master’s of Arts in 
Professional Communication program at Clemson University 
in August and has been willing to work full time for me 
now on the publication of ACORN.  Without her efforts at 
managing all of the details of the publishing process over 
the past three months, there would not be an ACORN.  
One of the academic words for how the process of starting 
an entrepreneurial company actually comes together is 
“bricolage.”  Entrepreneurs invariably need to “take what 
they can find at hand” (which is bricolage’s definition) and 
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use these resources to create the business.  Ali has proven 
to be an innovative “bricolager” at finding and using our 
limited budget to bring ACORN into being.  
The story of ACORN really involves a lot of other people, 
besides me, who enabled this publication to exist. I suppose, 
that would make for an interesting issue of ACORN: What 
if all of the people involved in the startup of a particular 
business were to tell their stories: the entrepreneurs, 
investors, employees, suppliers, buyers, and “significant 
others”)? Wouldn’t that be interesting to study?
Interviewer
One question: Why title the publication ACORN?  There 
seems to be a lot of controversy about the name “acorn” 
since, for some people, the word is associated with the 
organization ACORN (Association of Community 
Organizations for Reform Now).
William Gartner
Well, for me, entrepreneurship has always been about this 
saying: “from little acorns great oak tress grow.”  I think the 
oak tree analogy is very germane to creating and building 
businesses and for economic development. When we see a 
large business, we need to realize that it originally started 
small, just like an acorn.  There are only a few exceptions 
to this.  And, for every oak tree that grows large, there are 
thousands of acorns that tried to become oak trees and 
failed.  For me, that is the critical insight for business and 
economic development: we all want oak trees, but, oak trees 
begin as acorns, so, you start there, with the acorn.  
Jack Peck
Foxfi re Technologies Corporation
& FastFetch Corporation
Jack Peck has founded a number of different companies during his 
career.  This interview focuses on two of these companies: Foxfire 
Technologies Corporation and FastFetch Corporation.  Foxfire 
creates and sells software and hardware that collects data in real 
time on the manufacturing shop floor for sewing activities as well 
as software for managing the productivity of warehouses.  Jack 
sold this company in 2006.  He then started a new company, 
FastFetch.  FastFetch is a patented order fulfillment system 
built around a Personal Digital Assistant (PDA) that uses a 
combination of light directed picking, voice picking, and wireless 
scan picking technologies.  This interview was conducted in 
October 2007 during a class on entrepreneur-ship at Clemson 
University.  Since this interview, FastFetch has merged with a 
much larger, more established company, Wesley International, to 
form a new company called Wesley/FastFetch LLC, doing business 
as “Alexa.” Alexa had a major roll-out of products at the Promat 
Show in Chicago and the National Retail Federation Show in 





I was asked to come and tell you a little bit about some of the 
experiences that I have had with my company, Foxfire, which 
I started 20 years ago, but before I do that, I want to go over 
some of the other companies that I helped start.  I have been 
involved in some companies that have had successes and 
some companies that have had failures.  It is a lot easier to 
have failures, by the way, in case you are out to do one or the 
other.  But oftentimes there are good lessons to be learned 
through the failures.  I guess I always had an entrepreneurial 
spirit.  It is easier to look back and figure these things out 
now than it was at the time.  
My first entrepreneurial venture happened while I was 
attending graduate school in Louisiana.  I was approached 
by two people that were about 10 or 15 years older than me, 
who had decided to start a company, and they asked me if I 
would join them.  We started a company for which I was the 
technical resource and they were the experts in running the 
business.  The others were both CPAs.  
We were putting together computer systems in a company 
called TECH Data Systems: Technical Engineering 
Commercial and Hospital Data Systems.  I was developing 
software in all of those areas.  The company only survived 
for a little over a year before it was shut down because of 
illegal activities.  The two CPAs were running payrolls for 
hospitals and other groups.  They would print out a stack of 
checks for a hospital’s payroll system and would hand the 
checks to the hospital saying, “Okay, give us the amount of 
money equal to all of these checks,” and the checks would 
then be drawn against a common account for all customers.  
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Well that sounded like a reasonable way to do things.  The 
problem was that the CPAs were spending some of the 
money out of that account before the checks cleared.  Banks 
do that all the time, even today, but the problem was that 
they did not put the money back.  So they would have to run 
another payroll before the last checks cleared, which made 
them bounce for insufficient funds. They would have to run 
another payroll to cover deficits from the previous payroll, 
and the problem would keep being pushed into the future.   
They would do this using more than one bank account.  
Today, we call that “check kiting,” which is illegal.  
I did not know this was going on.  I was too busy writing the 
programs and making sure they all ran smoothly. I learned 
an important lesson: if you do not understand what is going 
on and you ask people to explain it to you but they cannot 
explain it to where you can understand it, maybe they are not 
telling you all the facts.  You need to understand everything 
going on in your business.  I learned that lesson pretty 
quickly. 
After that venture ended, I finished graduate school and 
came to Clemson University.  I am on the faculty in the 
Computer Science Department as an emeritus professor.  I 
started a group at the university that is still ongoing called 
The Division of Information Systems Development. This 
group does a lot of contract work for the state.  I ran that 
group for about four or five years, and it still exists today.  
We were doing work for about 25 different state agencies 
from the governor’s office down to Lander College.  At about 
this time was when I started my next company called Series 
One Incorporated, which ended in failure.  IBM, at the time, 
had a machine called a System 32, which became a System 
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36, which became a System 38, and then went on to bigger 
and better things. The System 32 was their commercial data 
processing machine, which many smaller businesses were 
using.  They also had another machine called the Series One, 
which was a process control computer. Its main functions 
were scientific and engineering applications. We discovered 
that the Series One had a lot of power, but it did not have 
the same software as the System 32.  Nevertheless, the Series 
One was a lot cheaper and a lot more powerful.  
So several of my friends and I got together and wrote an 
entire operating system, the System 32 Operating System 
and made it run on the Series One. We also wrote an RPG 
compiler and all of the rest of the software that had to go 
on it so the Series One looked like a System 32.  It really 
ran quite well.  We had investors in our company, Venture 
capitalists if you will.  We did not get a lot of money, but 
it was enough to keep us going.  We got a Small Business 
Administration (SBA) loan through a bank in Greenville.  
Then I found out that there was some behind-the-scenes 
dealing again.  I had no idea it was going on until it was too 
late.  As it worked out, the bank had made an investment 
in another company (with partial ownership by a relative of 
a bank executive) that was about to go belly up.  The bank 
then sold all of the assets of that company to Series One (as 
authorized by the Series One president who we discovered 
had interests in the failing company). This in turn drained 
all of the SBA resources away from us. We had no money 
to operate and had a bunch of obsolete assets that we could 
not use.  So, again I learned that even if the technical side 
is going well, the business side of it  can kill you if it is not 
done with proper controls.  So, I got out of that one.  That 
business only cost me about four months of salary. 
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I next started another business here in Clemson called Info-
Data Business Systems.  That one did not have any crooks 
in it, fortunately, but it was ahead of its time.  The business 
was doing things that became popular about 10 years later. 
The idea was to take small computers and move them into 
standard business applications.  Most businesses really were 
not ready for small computers just yet.  
Small computers, like the Radio Shack TRS 80, were more 
of a hobbyist thing rather than tools for running businesses. 
It was back in the old CPM days for those of you who may 
have studied a little history.  In any event, that company was 
a little ahead of its time, so the lesson we learned was that 
timing is pretty important.  You can have good ideas and bad 
ideas, but timing, getting these ideas into the market at the 
right time, is something that I learned from that experience.
I started another company after that called Apparel Soft. 
That failed, but I will not spend any time telling you about 
that.  Finally, I started a company for which I took all of 
my previous experiences into consideration and said, “I am 
going to start a company in which I know what is going on, 
and if it fails it will be because of my failures, not someone 
else’s.” I was a major player rather than a minor player.  I 
started it with another gentleman who now lives in Marietta, 
Georgia, and our company was named Foxfire Technologies 
Corporation, which started in 1987.  
We had an idea for a product, mostly software and some 
hardware we purchased from another company. Foxfire 
started with two of us (actually three of us, but we bought 
out the other person) pretty much in my garage.  Some 
people say, “Well why did you call it Foxfire?” Does anyone 
know what Foxfire is? It is a fungus that grows on dead 
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trees. Some people would say we named the company after a 
fungus, but that is not quite the way we did it.  If you go back 
to the roots of the term Foxfire, you will learn that it exists 
in the woods in the southeastern part of the United States. 
The best place to find foxfire is in the mountains. If you find 
an old stump or an old pine tree and you kick it over, when 
the inside of the stump is exposed, there is a mold that grows 
inside. At night, the mold glows.  Foxfire is the local term for 
the glowing fungus.
There was a fellow named Eliot Wigginton that taught 
English in a high school in northern Georgia. He had his 
students interview people up in the mountains—the old 
timers—about how they did things.  There is a series of books 
now, about 12 or 13 books, called the Foxfire books. They 
are a collection of chapters with directions on how to make 
dulcimers and soap and a lot of other things.   
We did not name our company after these books either. In 
reality, we were sitting around one day trying to figure out 
what to call the company, and we happened to be meeting 
in an apartment complex in Seneca, SC. The complex was 
named The Foxfire Apartments. We argued and nobody 
could agree on a name.  So we just threw our arms up and 
said, “We should just name it Foxfire after the apartments 
where we are meeting.”  So, we were named after an 
apartment building complex. It is a catchy name, and people 
have generally heard the word Foxfire in this part of the 
country. But, Foxfire often gets confused with Firefox, the 
Internet browser. 
When we started Foxfire we got our first contract with 
a company called Tultex, a large apparel manufacturing 
company in Martinsville, Virginia.  Our software product 
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collects data on the manufacturing shop floor, in real time, 
for sewing activities.  At one point, Tultex had around 
10,000 employees.  In some of the plants they had about 
2,000 people sewing in one great big building. I do not mean 
to tell you too much about apparel manufacturing but a little 
might be helpful in terms of understanding the complexity of 
an apparel operation and the problem we were solving.  
To make a shirt, there are approximately 40 operations 
to be carried out. Some of them include sewing the hem, 
sewing the buttonholes, sewing on the buttons, setting 
the sleeves, etc.  First the shirt fabric is cut; then multiple 
plies of material are laid out, typically about 40 plies high. 
A reciprocating knife cuts out each piece (the sleeves, the 
fronts, and the backs), and the pieces are all placed into 
stacks. There are stacks of 40 collars, 40 sleeves, 40 fronts, 
etc.  The stacks move through the sewing floor in parallel. 
One collection of people work on the sleeves, another 
collection of people work on the fronts, and so on.
Typically there are about 10 to 15 garment subassemblies 
traveling independently through the sewing floor, and 
they have to come together for final assembly to become 
a finished product at some point.  The aim of the Foxfire 
software is to make sure that the sleeves are moving at the 
same rate as the collars and the fronts. This way they will all 
come together at the same time for final assembly.
This is a non-trivial task, particularly when you have 2,000 
people sewing on different stacks of subassemblies all over 
the factory. Typically, we have about 200,000 to 300,000 
work-in-progress units going at the same time, and keeping 
track of all of this is very important. Also, keeping track 
of the efficiencies of the employees is necessary because 
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these people are paid by piece work. The Foxfire software 
increased the productivity of employees between 15% and 
25%, representing a lot of savings.  We installed the Foxfire 
software system in many other companies including Brooks 
Brothers, Wrangler, and Levis Straus. 
Interviewer
Why did you choose the apparel industry?
Jack Peck
I started the company back in 1987 while working as a 
faculty member at Clemson. As a professor you experience 
forced unemployment during the summers. Well what kind 
of industry did we have in the SC Upstate back in 1987? 
Textiles and apparel companies were predominant.  Textile 
people make the cloth, while apparel people sew the cloth 
together into garments, seat covers, clothing etc. 
The original Foxfire software was a fairly complex system, 
and it is still being run offshore in places like El Salvador 
and Mexico.  Most of the textile and apparel industries have 
moved offshore in recent years. I have spent a lot of time in 
El Salvador installing and training people on the software.  
So the system is multilingual, and right now, we are looking 
to move it into the Far East (China) because that is where the 
apparel industry has gone.  
Interviewer
How did you come up with the idea for this real-time system?
Jack Peck
I had done consulting during the summers with some 
industrial engineers who were in apparel manufacturing. I 
went into plants with them and just watched what they were 
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doing and thought, “Man, there has got to be a better way.” 
When I saw how they were collecting the data, it seemed very 
inefficient to me. 
For instance, if I am the person sewing the collar, attached 
to the collar is what they call a “gum sheet.”   A gum sheet 
is a collection of coupons.  Each coupon represents an 
operation that has to be carried out on each bundle of parts. 
The employee takes the coupon and sticks it onto a sheet 
of paper, which marks the task as completed. Every time 
you complete a task you have to make a record of what you 
have done so you can be paid accordingly.  The clerical work 
involved with the coupons took up about 20 seconds for 
every single bundle, and workers might complete around 
100 bundles per day.    The coupon system is inefficient 
because you are paying employees for clerical work rather 
than sewing.  So I said to the engineers, “If we can cut down 
on that clerical work and reduce it from 20 seconds to two 
seconds, it will result in a huge savings in terms of labor 
increased productivity.”  
Our system became very popular.  It was a little more 
difficult to market a system like this offshore simply because 
the labor rates are lower.  They’ll just say, “Okay, so what 
if it takes 20 seconds more?  I am only paying $0.50 an 
hour.” There is a lot less incentive for them to become more 
efficient.
We eventually started to look at logistics to see if there 
were any opportunities in that area.  This was when we 
started creating a warehouse management system. The 
way warehouses operate seems rather mundane. You take 
something off of a shelf, you put it in a package, and you 
mail it. However, there is a lot more to it than that.  
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One of Foxfire’s biggest customers is Alltel Communications. 
Alltel has approximately 3,000 stores across the country all 
of which are shipping orders late in the day while expecting 
them to be delivered next day via UPS.  In order to fill all 
of the orders quickly and accurately in a short timeframe 
is very difficult.  When we originally went into Alltel, the 
warehouse was a complete mess.  
We implemented our system into their warehouse and 
smoothed out their operation considerably. With their old 
system, Alltel was running three shifts seven days a week 
and still were not getting their work out. They were working 
people overtime and incurring a lot of extra costs. Today, 
they are shipping twice the volume and are only running one 
shift five days a week.  You can see the kind of savings that 
they are looking at on labor, customer satisfaction, as well as 
many other aspects that are byproducts of doing a better job.  
Interviewer
How did you integrate your software with what they already 
had in place?
Jack Peck
We replaced what they had.  We did have to do some 
integration because there are things that Foxfire’s software 
does not do. For example we do not have an order entry 
system.  Their ERP (enterprise resource planning system), 
which addressed their accounting issues, order entry, and 
billing, was already in place.  So, we had to interface with 
their ERP. When an order comes in, we pick it, get it packed, 
and ship it. The transaction transfers back up to their 
corporate computer that says, “You need to bill these folks 
because here is what we just sent them.” There is a fairly 
clean interface.  
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Orders come down, and information goes back up.  Of 
course it is a little more complicated when an order from 
a supplier is received because we have to know that it is 
received.  We have to put the inventory away, know where 
we put it, and be able to call for it when the time comes. 
There are perishable issues for some products, so you want 
to get rid of the oldest first.  There is replenishment; there is 
consolidation.
The Foxfire manufacturing systems are still being sold, but, 
in the United States, the only customers who are buying 
and operating this system are a protected species called 
“government contractors.”  There is a law called The Berry 
Amendment that says all sewn products for our military 
must be made and purchased in this country if they are at all 
available.
Right now, Foxfire software controls the manufacturing 
process for 100% of the chemical protective suits made 
for our military. The chemical protective suits are a little 
different from your standard shirt or pair of socks in that you 
have to have a complete pedigree for the product. If there is a 
problem down in the field with the garment, we have to trace 
it back to what sewing machine sewed it, what raw materials 
went into it, who was running that sewing machine precisely 
when it was made, and what kind of thread was used.  After 
that we have to go forward to see what other products were 
made using that sewing machine, which person was sewing 
on that machine, etc. 
One of the most important things that I learned from 
Foxfire was that when we started to get key employees, we 
needed to give them some interest in the company.  We felt 
it was important that they be invested in and dedicated to 
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the company. The second thing was that the two of us who 
started the company had an agreement that we would receive 
the same compensation out of the company independent of 
who did what.  That way we would not look at each other 
and say, “Well I did a little more than you last month, so 
I ought to get a little more than you do.”  We just said, 
“Okay, we are all going to do what is required, and whatever 
compensation one gets, the other gets.”  
My partner was full time and I was part time.  At the time, 
I was  teaching at Clemson and continued there until 
2000 when I retired.  One of the reasons that I formed the 
company was to be able to put my kids through college. At 
one time, I had my wife and three kids going to college at 
the same time.  The sum of the tuitions exceeded my take-
home pay from the university, so I had to have some outside 
income.
In any event, my partner was working full time at Foxfire, 
and I was working at Clemson.  So, we took my Clemson 
compensation and my compensation with Foxfire and 
made it collectively equal to his compensation with Foxfire. 
This worked out really well for us since no one complained 
that one person was doing more work than the other.  My 
partner’s specialty was not technology related; rather, his 
specialty was in the business aspect of things.  He has a 
Master’s of Business Administration, so his background was 
more in the financial side and mine was in the technical side. 
We always kept an eye on each other, too.
Interviewer
How big did the company get, and how big is it now?
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Jack Peck
The largest we got was about 40 employees in the United 
States, but, overall, we had 50 employees because we opened 
an office in India.  I failed to mention that.  Back in the 
dot-com era, when the dot-com growth was really heading 
sky high, it was tough to get good technical people. We could 
not hire them because they were all moving to California to 
become wealthy, my son included. So it was difficult to get 
good people.  
One of the people we hired was actually a former student 
of mine, an Indian student who had good connections in 
India.  We opened an office in India to start development. 
That office is still doing development for us today. We have a 
decent number of people in the states as well.
U.S. employees design the software, ship it off to India to get 
the initial implementation done, get it back from India, make 
sure that it is done the way that it was supposed to be, kick 
the tires, fix any problems, and finally install it at customer 
sites. We felt like it was important to have maintenance 
and support going on in the United States versus in India. 
If someone says, “My warehouse is down.  I cannot ship 
my product,” we put somebody on an airplane, and within 
four or five hours, he/she is there on-site trying to fix the 
problem. We do not do this very much, but it makes our 
customers feel that, if necessary, we can do that. It is a little 
tough to do that from other countries.
Foxfire is now a growing company with new owners. The 
new owners of Foxfire had been chasing us for a while. They 
are former Datastreamers.  Datastream was a company in 
Greenville that was bought out by a company called Infor 
about two years ago. One of the Datastream owners, a man 
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named John Sterling, had a non-compete for a year.  So, 
after a year he jumped in and bought Foxfire and is going 
to do with Foxfire what he did with Datastream.  He took 
Datastream from $600,000 a year gross sales to over $100 
million a year. He sold Datastream for $224 million. His idea 
is to again take a small company and build it up.
Interviewer
Did your partner stay with you the entire time?
Jack Peck
Yes.  We are still partners in our new venture.  We stayed 
together for 20 years while Foxfire grew.  We sold in 2007.
Interviewer
What kept you together for 20 years?
Jack Peck
Well, we kept making money.  We kind of liked that. We 
never operated in the red from the day we opened the 
door. We treated our employees’ right as far as benefits 
were concerned.  We had hospitalization and dental.  We 
paid 100% of the premiums on all of those benefits, and 
we had really good policies.  We had what is called an SEP: 
Simplified Employee Pension plan, which is like a 401K. 
We fully funded every year since we started it, which was 
the whole history of the company.  The employees made 
no contribution. We gave bonuses at the end of each year 
depending on how well the company did. In some cases the 
bonuses were greater than their annual salaries. We treated 




Did you and your partner get into any conflicts, and if so, 
how did you resolve those issues?  
Jack Peck
We took a vote, and I always won.  No, we did have some 
differences of opinion.  You are always going to have 
differences. I gave in sometimes, and he gave in sometimes 
depending on the nature of what we were talking about. We 
rarely compromised in the sense that we took the middle 
ground between two positions.  Sometimes that does not 
work very well.  
If it was something that was more business related. I just 
let him have his way. If it was related to how we were going 
to spend money, if we were going to hire another technical 
person, who we should hire, etc., he pretty much relied on 
me and my technical expertise in that area.  
Interviewer
I am very interested in the sequence of actions during the 
initial stage of creating Foxfire. Did you form the company 
before you had your first sale? How did that work?  When 
did you have your “first sale,” and when did you start 
development?
Jack Peck
We had a contract in hand, and then we formed our 
company.  Our customer, Tultex, was contracting with me, as 
an individual, for this product. They said, “Go ahead and do 
it.”  So we said, “Let’s draw up the document, the contract, 
precisely describing what we are going to deliver, how much 
it is going to cost, how long it is going to take, etc.”  We drew 
it up, and then we formed the company. Then, that contract 
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was assigned to the company because we felt it was important 
to have some sort of protection. 
Interviewer
What do you feel brought them to the table as you were 
negotiating the contract?  
Jack Peck
What convinced them to do business with us?   The idea.  
This was an idea they had been asking themselves about: 
“How can we cut costs and increase production; how can we 
do it?” We told them how we could do it, which they had 
never considered.  They said, “Well these guys are pretty 
creative and pretty bright, so let’s take a chance on them,” 
and it worked out fine for everybody.  
Interviewer
What kind of capital did you use to start the company? 
Jack Peck
Nights, weekends, and sweat equity.  We had no capital. We 
drove our own cars, we paid for our own gas, and we took 
no money in terms of salary.  I had a PC, a little bit of time, 
some development software, and that was all.  
After we delivered our first product and we had a showplace 
we could take people to, we started getting a lot more 
business. Then we asked ourselves how we were going 
to market because the first time we had sold before we 
developed. At the time, we had an offer from a venture 
capitalist to put some money in.  He wanted a big hunk 
of the action, and we decided that we would not go that 
direction.  We decided to grow more slowly with less money 
rather than faster with more money.  
26 FOXFIRE
So that may have been a bad decision.  I am not claiming 
that it was the right decision.  That was just the decision we 
made.  In fact I suspect that, particularly when it came to the 
warehouse management side of the business, we actually had 
products before any of our competition. They beat our pants 
off, though, because their companies grew faster with more 
capital.  
They grew a lot faster and a lot bigger. The guy that I knew 
who started Manhattan Associates sold his interest for $400 
million when he cashed out.  He did pretty well.  He took 
the venture money and grew faster, and that was a better 
decision.  I will have to give him that.  
In any event, those are choices you need to make, go slowly 
and maintain more of the company or grow faster and give 
away part of it.  There is no right answer.  There is just a 
thoughtful answer.  We are growing slowly right now with 
my new company, but that could change.
Interviewer
When you made your first contract, it appears that you 
arranged, as part of the deal, that you would develop the 
product for Tultex, but you still had the rights to it, and you 
could sell the product to other companies.
Jack Peck
Yes, that was known right up front.  We were not just 
consultants for hire.  We were developing products that we 
would own, and they would buy licenses to.  We gave them a 
really good price, as you might imagine, because of that. We 
did not sell products; we sold licenses to products. Obviously, 
if you sell a product to someone, they own it and can do 
what they want with it.  So we sold the license to the product 
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and the support services. We also ended up selling a lot of 
media, i.e., paper.  
When the company ships products from their warehouses, 
they have to put little labels on them that says where they 
will go, the shipping labels.  You would be surprised how 
much money there is in shipping labels.  If you can make a 
nickel on each one it really adds up.  So we would go into a 
company and say, “Our normal license fee is $96,000.00 for 
this software.  We will give you a 50% discount if you will 
agree to buy the media from us.” They have to buy it from 
somebody, so why not us, right?  
They would jump on that, and it ends up being an annuity 
for us that they pay year after year.  It does not take long 
before it exceeds the $48,000.00 discount that was given to 
them.  This was not my idea; this was my partner’s idea.  A 
lot of companies like to do things this way because shipping 
costs are coming out of a different budget.  
Interviewer
Why did you sell Foxfire?
Jack Peck
I mentioned one of the reasons, money.  The other reason 
was FastFetch, my current company.  I had an idea walking 
through a bunch of warehouses and seeing how people were 
doing things.  
Interviewer
How did you come up with the name FastFetch?
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Jack Peck
We tried to have catchy words, and with Foxfire, I had an 
idea when I was Chairman of the Board. Let me tell you a 
little about the idea behind FastFetch before I answer your 
question about the origin of the name.
My idea was to figure out how to fix things in warehouses 
as far as picking, shipping, and other operations.  An order 
comes in, and you have to get all of the inventory items 
together, put them in a box, and ship it.  That picking 
process is where more labor is spent in a warehouse than 
any other place.  A lot of the big retailers like Walmart and 
Target will charge you a lot of money if you do not ship them 
precisely what they ordered. These penalties are known as 
“charge backs.”  They will charge you back a lot of money for 
doing it wrong.  
Sometimes the charge back exceeds the cost of the 
merchandise that you sent them. In this case, they will 
deduct the charge back from your bill before paying it. There 
are many companies that are very sensitive to charge backs, 
as it costs them millions of dollars a year.  So, when you  say, 
“I can show you how to pick your product three times faster 
with 100% accuracy,” you get their attention. I figured out 
how we could develop technology that will allow you to do 
just that: pick about three times faster with 100% accuracy.  
So, I applied for a patent on it, and as soon as the patent was 
granted, we began development.
We did not want to start development until we knew we had 
patent protection.  When we started development on the 
product, the entire project was funded by Foxfire because 
development was happening inside of Foxfire. One of the 
people who I called in to help on the project was Ed Page.  
ACORN 29
He used to have an office right above this classroom (in 
Brackett Hall).  He was previously the Director of Technology 
Transfer, and he was the head of the Clemson University 
Research Foundation. About a year ago, he retired from 
Clemson and joined me at FastFetch. Ed and I were also 
colleagues in the Computer Science Department.
Ed came in and we worked on the development of software 
as well as hardware.  We developed and designed a lot 
of hardware and prototyped it.  Ed was not an owner of 
Foxfire, but he was a strong participant in FastFetch, the 
new company.  At that time, it was not called FastFetch: our 
product was called FoxFetch. FoxFetch is “fetching” stuff, 
meaning picking.  We showed the technology at a trade show 
and got a good reception.
We thought our product had the potential to take off. 
FoxFetch, as a product, had no history of sales.  We had been 
developing, getting patents and intellectual property, doing 
designs and prototypes, and arranging for manufacturing in 
China.  FoxFetch had been nothing but a drain of resources.  
We worried that when someone eventually came in to buy 
Foxfire, whether they were going to value the FoxFetch 
product at zero or even a negative value since there was no 
history of sales.  We decided to move the FoxFetch product 
into another company. We ended up naming the company 
FastFetch.  We did not want to call it FoxFetch because this 
product not only runs with Foxfire software,  but it also runs 
with all of Foxfire’s competitors’ software.  It is an adjunct 
to a warehouse management system.  So, we did not think 
our competitors in the warehouse management system arena 
would be too happy about sending their customers to deal 
with one of their competitors. We wanted to completely 
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separate this product from Foxfire to avoid conflicts, and it 
has worked out really well for us.  
We formed the new company, and gave Ed 25% of it. The 
other Foxfire shareholders got the other 75% collectively, in 
proportion to their ownership in Foxfire. This included some 
of the employees who had a stake in Foxfire at the time.  It 
was a good way to do it, and everyone was pleased. FastFetch 
was then formed in August 2006 and is a little over a year 
old now.  We have had some very good press and were picked 
as one of the eight most innovative products of the year in 
warehouse management systems.  
We have had some reviews by some of the major companies.  
You have probably heard of Gartner and Forester Research.  
There is another company called Aberdeen Research with 
the Aberdeen Group.  They did a review and had a very nice 
report of our product.  We did a head-to-head test against 
Levi Straus’ best system for picking in a warehouse and beat 
them three to one in picking efficiency with 100% accuracy.  
We have been very pleased with our progress to date.  We 
have two customers now, one of them is a company called 
A Beka Book.  I do not know if any of you have heard of A 
Beka Book, but they are the largest publisher of Christian-
based, home school, and educational materials in the world.  
They are located in Pensacola, Florida.  A Beka Book is part 
of the Pensacola Christian College.  They are actually the 
major source of money for Pensacola Christian College.  All 
the profits from A Beka Book help fund the school.  Instead 




Is your software web based or is it non-web based?
Jack Peck
In terms of Foxfire, we have some Web- and some non-Web-
based software.  It is not an issue of what works best and 
makes sense.  The problem with the Web is that you cannot 
process 100 transactions a second, but you can with a local 
area network.  We are very sensitive to the real-time aspects 
of operations. Typically, the software is not Web based.  
Interviewer
What business problems does FastFetch solve?
Jack Peck
Imagine a warehouse.  A warehouse has racks and bays with 
products that are on shelves. Pickers walk through with an 
order and pick out the products they need to fill the order. 
They walk through the warehouse, generally with a cart or a 
tote, and put the products into an order box.  It takes a long 
time to be able to pick more than one order at a time.  We 
call that batch picking: multiple-order picking.
So, with FastFetch we put order boxes on the cart, we get a 
download of orders consistent with the capacity of the cart, 
for example 10 orders, into a PDA.  The entire system runs 
on a Personal Digital Assistant (PDA).    We developed some 
hardware that allows us to link the PDAs to lighted numeric 
displays (lights).  One lighted display sits under each order on 
the cart. 
The PDA verbally tells the picker where to go, what to pick, 
and how many of each item to pick.  If you have a cart with 
10 order boxes, there will be 10 lights.  If you have a cart 
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with 200 orders, you have 200 lights, one sitting underneath 
each order box on the cart.  Similarly, at each bay location 
we have a lighted numeric display. When you push your cart 
down the aisle, it tells your PDA where to go first.  There is 
an infrared signal sent from each PDA that “polls” for the 
bay to pick from.
When the picker reaches the right the bay, the PDA says, 
“Stop,” using a combination of voice and visual prompts. 
The PDA sends the signal out to the bay and lights up the 
numeric displays (with a “5,” for exampe) where you need to 
pick.  It will say, “Take five of that item.”  When you look 
over at the cart, there may be lights under two boxes: one 
with a two and one with a three both of which are lit up.  
So, the first order needs two of those five products, and the 
second order needs three of them.  This is called cluster 
picking. The system allows workers to pick very quickly with 
no paper.  It tells you verbally where to go and when to stop. 
If you go to www.FastFetch.biz there is a video you can look 
at of the system in operation.  It is about 14 minutes long, 
and it tells you a lot about the system in greater detail.  
Interviewer
Does the system require a lighted numeric display under each 
product in the warehouse?
Jack Peck
Well that is a good question.  First of all, there is one other 
feature of FastFetch that helps lower cost. If you pick a 
certain product once a year you probably cannot afford to 
put a light on that location.  That is pretty clear.  So, what we 
have done is to integrate a Bluetooth scanner and a barcode 
scanner.  If it directs you to a location where it knows there 
is no light, it will tell you verbally to go over and scan the 
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barcode on the product.  At that point, you have confirmed 
that you are at the right spot.  It then tells you verbally to 
pick a certain amount, for example “three.” You grab three, 
turn around to the cart, and the lights on the cart tell you 
which cart location (order) to put them in. Abeka Book, in 
their first phase of installation, had no lights on their bays. 
The only lights were the ones on the carts. They were using 
Bluetooth scanning to confirm that their workers were at 
the right bays. The Bluetooth signal is not as fast as the light 
calling your attention to the bay. Most people use what is 
often called the 80/20 rule: you put lights in 20% of the 
products that generally represents about 80% of your picking. 
So, about one-fifth of the cost buys you 80% of the benefits.
Interviewer
Are you competing against companies that are developing 
their own systems, like Amazon?
Jack Peck
Amazon and some of the others are using several different 
methods.  Let me talk about the competing technology, 
which companies like Amazon use. Competing technologies 
are, of course, mostly paper, which is not a terribly 
competitive technology. Another technology is carousels. 
Carousels have locations that rotate.  When you say, “I need 
something,” it rotates until the item you need is presented. 
However, it can take up to a minute for the carousel to 
present the product to you, which can be a very inefficient 
and time consuming.
Interviewer
What do companies like Walgreens use?
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Jack Peck
Walgreens uses some carousels as well as other things too, 
but the advantage of carousels is that they do not take up a 
lot of floor space. You do not need the extra space to be able 
to walk between aisles. 
Another technology is radio frequency (RF) picking. With 
RF picking, there is typically a portable handheld barcode 
scanner that receives a radio signal and tells you where to go 
on a little screen.  It reads something like “Go to location 
R-15-023-014.” When you get there, you have to scan either 
the product or the location barcode, which is very similar to 
what we were talking about earlier.  Typically you are doing 
a single order at a time. You scan the product, put it into a 
box, scan another one, put it into the box, and so on.  Most 
companies that use RF picking do not do multiple-order 
picking.  It is very slow to make a trip through the warehouse 
for every order; it can take you up at an hour to fill an order, 
particularly if you have a large warehouse. 
We have developed special optimization techniques using 
what we call genetic algorithms.  I do not know if you have 
heard of that term, but they borrow from the principles 
of biology.  Say you have 200 orders.  If your cart has the 
capacity for six orders, then you ask: “I wonder which six 
orders (out of perhaps several hundred possible orders) I 
ought to put on this cart.  I would like to fill similar orders 
at the same time, so I will not have to walk too far in the 
warehouse.”  So how do you determine which six orders are 
the best in terms of minimizing the travel time through the 
warehouse?  It is a tough problem. It is what we call an NP-
complete problem in computer science terms, meaning that 
the time to solve it is not proportional to any polynomial 
function.  We have developed some very clever algorithms to 
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do that. It is fun taking some of the concepts pertaining to 
computer science and actually putting them into action by 
building products.  
Other types of technology you see in picking are pick-to-light 
systems. They are similar to what I was talking about with 
FastFetch.  The biggest difference is that the lights are only 
on the bays, not on the carts.  So you are typically doing one 
order at a time and have an automated conveyor delivering 
the boxes from one place to another.  The problem with 
this is that you can only pick one order at a time. Also there 
is a central computer in the back room that controls all of 
the lights in the entire warehouse.  Your first light with that 
system typically costs you about $150,000; whereas, our first 
light costs $50.00.  So you can see that we are into an area of 
the marketplace where we are very competitively priced.  We 
do not have the big infrastructure that you have with pick-to-
light systems.  
There are a few other types of picking technologies.  There 
are products called A-frames that are really high speed, but 
we are not competing with those. They are primarily used 
for drug wholesalers or cosmetic supply companies like Avon. 
It is called an A-frame because the picking device looks like 
an A-frame house.  A conveyor runs down the center of 
this big A-frame; there is a box on the conveyor, and as it 
moves through the A-frame, it shoots out all of the ordered 
products into the box.  It is highly automated. 
I mentioned earlier that we currently have two customers. 
The second customer is a company called GENCO, which 
is in Pittsburgh.  GENCO is the third largest third-party 
logistics company in the United States.  A third-party 
logistics company is a company that runs warehouses for 
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other people. The products in their warehouses do not 
belong to them; they just run the warehouse for a different 
company. They put the stuff in the warehouse, take it out, 
pick it, pack it, ship it, and provide the labor. Sometimes, 
they own the physical building, and sometimes they do not. 
GENCO is very large and is right behind UPS and FedEx in 
terms of size.  They did a test of our system and had a third-
party industrial engineering company come in to monitor 
the test. They used their own system that they produced 
internally, and we beat them three to one. They are going to 
be putting our system into many of the warehouses that they 
run around the country.  We are looking forward to that.  
In terms of the development of the business, right now 
we are part the SC Launch! program, a program which is 
administered by the South Carolina Research Authority. 
What they are trying to do is help entrepreneurs who have 
good ideas start companies in South Carolina.  In order 
to become part of that program, there is a fairly involved 
questionnaire. There is also a multi-page document that you 
have to fill out explaining your business plan.
That gets you into the program, and with that, you get a 
network of people who can help you.  The second part, if 
you are interested in continuing, is to get some initial capital. 
You can get up to $200,000 from SC Launch! in the form 
of a loan.  Like all loans, you are expected to pay it back; 
however, the difference between this loan and a loan from 
a bank is collateral. You do not put your personal assets on 
line with SC Launch!, as you would with a bank.
Now if you cannot pay the loan back, SC Launch! takes part 
of your company.  They will take interest in your company, 
a percentage, which is determined by different factors 
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depending on how well you are doing at the end of the 
period. At this point, we have filled out all the applications 
and are in the process of going through what they call “due 
diligence” with the SC Launch! program.  We are hoping to 
become part of that program and get additional funding.  
We were recently nominated by a group called Innovision in 
the Upstate to receive an award.  Innovision is a group that 
fosters and promotes the development of technology. There 
are big companies like Michelin, BMW, and Fuji as well as 
few small companies like FastFetch. We were selected by the 
Innovision group as one of the three finalists to receive an 
award.  In November, we will find out the results, but it is an 
honor to be one of the final three. 
I might say that the FastFetch product is also good for 
companies similar to BMW suppliers. Within a 20-mile 
radius of their plant in Spartanburg, BMW has about 85 
different suppliers. BMW gives them an electronic order, and 
within two hours, they are expected to have materials at the 
BMW headquarters ready for the production line. 
For instance, say that BMW plans to assemble 300 cars.  
If I am the wiring harness supplier, they will send me an 
electronic order for 300 wiring harnesses all of which could 
be different.   The pickers must very quickly and accurately 
pick the correct wiring harnesses. The added complexity of 
the BMW picking problem is sequencing the picked items 
onto the cart.  The first position on the cart must have the 
wiring harness for the first car; the second position must 
have the wiring harness for the second car and so on. Not 
only do the workers have to pick quickly and accurately, but 
they have to sequence them onto the cart in the same order 
as the production line.  
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That is a tough problem for people to do in two hours.  Our 
technology will do that very quickly too because it lights the 
light on the cart, which tells precisely which location to put 
the picked item for each particular car.  We are targeting that 
marketplace as well as anybody who does replenishment:  
convenience stores, pharmaceuticals, auto parts suppliers, or 
anyone who takes point of sale data or customer orders that 
come in very quickly.  That is the target market that we are 
looking to be involved with, and there seems to be a lot of 
companies in it.  We are very excited about the future.  My 
plan, if everything works out, is to build the company for 
about three to five years and then sell it to a larger company. 
At Clemson there is PTR: Post Tenure Review, a process I 
went through when I was a Department Chair.  PTR forces 
the University to examine the tenured faculty periodically to 
make sure they are all productive.  We were joking the other 
day and saying if they start a PRR, Post Retirement Review, 
process, I am in trouble.  I have not been doing it properly, 




Dee Cross is the founder of Equi-tox Pharmaceutical Research & 
Development, a company that discovers and develops innovative 
products to improve animal and human health, directly and 
through partnerships.  He is a Professor Emeritus of Animal and 
Veterinary Sciences at Clemson University.  Equi-tox was founded 
in 1995 to search for ways to alleviate the pain and suffering 
of fescue toxicosis in horses, cattle and other animals grazing 
on endophyte-infected fescue.  This interview was conducted in 
October 2007 at Clemson University.  Since this interview, the 
company has continued with drug development to include over 150 






I am originally from Kentucky and have a Master’s and a 
PhD from the University of Kentucky. I became a professor 
at Clemson University on January 12, 1973 and taught in the 
animal and veterinary sciences department, even though I 
am not a veterinarian myself.   I retired in 2004, as Clemson 
no longer needed my services.  
I grew up on a farm in Western Kentucky.  My dad was 
primarily a root-crop farmer and, as a result, did not take 
very good care of our livestock because they did not generate 
as much income as his crops. So after a while, taking care of 
the animals became my job.  As a result, I became interested 
in livestock and continued in school studying biological 
sciences.  I majored in animal science as an undergraduate 
and minored in chemistry and biology. Then, I went to the 
University of Kentucky and earned my PhD in nutrition and 
a minor in biochemistry. After graduating, I decided to come 
to Clemson and began teaching PhD students in the animal 
physiology program.  
However, after a number of years, I started a new focus in 
nutritional toxicology.  I began this new focus by teaching 
pharmacology to PhD students.  Many of these students went 
into medical fields or became physiologists.  I combined my 
background in pharmaceuticals and animal science, and the 
result was nutritional toxicology.  
In 1987, I began to research a problem concerning a toxin 
in grass-grazing animals. The most predominant grass in 
the United States is a grass called fescue.  When you look 
around campus, the green grass that you normally see is 
fescue, which was released a number of years ago by the 
University of Kentucky after originally being imported from 
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Europe.  I am going to tell you a little story about how we 
started with fescue grass and how our work evolved into the 
startup company, Equi-Tox, at Clemson University.
For years, we noticed that cattle feeding on fescue were 
not performing as they should.  In fact, they seemed to be 
showing signs of toxicity.  A plant pathologist working for 
the USDA finally figured out that fescue had an endophytic 
fungus. This fungus is quite unique because it grows inside 
the grass; while most fungi are external.  You usually see 
fungi blowing in the air or growing on various things, but 
this one was quite deceitful in that it was hiding in plants. So 
we combined “endo,”meaning inside, and “phytic,” meaning 
plant, and called it an endophytic fungus.
It turned out that this fungus was producing certain toxins, 
which were really natural pesticides.  Many plants have 
protective mechanisms, which is exactly what this fungus is 
for the fescue grass. The plant’s development of this fungus 
was a protective genetic phenomenon: the endophytic fungus 
releases toxins that make the fescue a very hardy type of 
grass that is thus able to grow throughout the United States. 
The fungus’ toxins are essentially natural pesticides that keep 
insects from eating the plants and also make the grass more 
drought-resistant. There is a kind of a symbiotic relationship 
between the plant (the host) and its endophytic fungus.  
However, it was causing problems for livestock.
We began to notice that when the cattle grazed on fescue 
grass, their respiration rates were very high, they were not 
lactating or milking as well, they had lower weight gain, they 
were panting abnormally (especially in the hot summertime), 
their body temperatures were higher, and they had problems 
with their hooves.  
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In very toxic cases, the worst-case scenario would be that 
the toxin was so bad that it caused vasoconstriction in the 
limbs and crippled the cows. There were even some cases 
in which the cows’ feet would come off at the ankles due to 
vasoconstriction, and in the winter, poor blood circulation 
also caused the tips of some of their ears to fall off.  So, this 
toxicity was an obvious problem for cattle.  
Approximately 100 researchers in the United States (at least) 
were working on this problem because it was a significant, 
multi-million-dollar issue in terms of livestock production. 
Initially, I chose to concentrate on equine toxicosis primarily. 
Others observed that horses grazing on fescue showed more 
severe toxicity symptoms as compared to other animals.  
However, prior to our work, no one had ever run a control 
study to document these findings.  So, I set up what is called 
a two factorial controlled study in which I had horses graze 
on the infected fescue—we called it fungus infected—and on 
fungus-free fescue.  
At that time, plant breeders had bred a type of fescue that 
was fungus-free.  We thought, “Well, that’s the solution,” 
but this grass did not solve the problem because without 
the fungus, the plant was not hardy. The grass did not have 
that symbiotic relationship or those natural pesticides, so 
it did not produce as well.  As a result, if we had a hot, dry 
summer, we would lose the plant, and if we fertilized it, the 
production was low.  So, we ultimately had to quit using that 
particular type of grass on a large scale.  
However, we did use it in our controls and were able to 
document the exact effects the toxins had on horses.  For 
example, the average gestation length before a mare has foal 
is about 338 days, or approximately 11 months.  However, we 
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found that the mares that grazed on the endophyte-infected 
fescue had gestation periods of about one year, almost a 
whole month longer than normal.  You can imagine the 
effects of going a month longer in gestation before foaling! 
No wonder these horses were having such bad problems.
Also, we found that about half of the mares had stillborns 
at foaling because the foals were encased in the placenta. 
Some of them suffocated because the placental membrane, 
what we call the chorioallantois, was thickened, making it 
too difficult for the foals to break through. When a foal 
is born, he wants to break his nose through the placental 
membrane, take a big breath, and come alive.  However, 
when he takes that big breath without breaking through the 
placenta, he just pulls the chorioallantois up against his nose 
and eventually suffocates. You can cut the foals out and save 
them if you get there in time, but normally they suffocate 
because the mare gives birth when no one is around.
Also, almost all of the mares feeding on the infected fescue 
(except for one) were what we call agalactic: they did not 
have any milk.  On the other hand, all of the mares on the 
good fescue (again, except for one) were milking fine.  So, 
we found that the infested fescue caused a huge problem in 
the mares’ lactation.  There were also higher rates of what we 
call placental retention afterbirth in addition to rebreeding 
problems; the mares on the infected fescue could not breed 
as well after their initial foaling.  Some of the foals whose 
mothers were on the infested grass did live, but they were 
not has hardy as the other foals, at least not for about three 
weeks after birth. Once the mares were off the toxic fescue, 
they recovered and did pretty well, though.
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But there was an even bigger problem: the mares feeding 
on the toxic fescue had dystocia, or foaling difficulty, and 
were not prepared for foaling.  Their gluteal muscles did not 
relax; their vulvas did not swell; their udders did not develop; 
and their cervixes did not relax enough for the foals to pass 
through.  A good corollary to this situation is trying to pull a 
tennis ball through a shotgun; you just cannot do it, and you 
are not going to be able to save the foal in such cases. Almost 
100% of the foals who birthed in these conditions died.  
What we were trying to do at that point was save the mares, 
and they were so unprepared for parturition that we lost a 
high percentage of them during the birth process as well.  
So, as you can tell, the result of the toxic grass had horrible 
effects on horses.
I had a graduate student, Jim Strickland, who worked 
on this.  He was a great student and got his PhD here at 
Clemson. Now, he directs a whole team of USDA scientists 
at the University of Kentucky doing research with forages 
and livestock.  When he was working on this study, we 
developed a bioassay for these toxins, which we discovered 
were ergotalkaloids. This bioassay was very important 
because it enabled us to study the toxin’s mechanism of 
action.  However, developing the bioassay was difficult 
because assay techniques at the time were very complicated.  
So we developed this bioassay system that enabled us to pull 
tissue slices out of the pituitary glands of rat brains and still 
keep them alive.  After we removed these slices, we perfused 
them with toxic alkaloids. The pituitary is located at the back 
of the head, close to the brain; part of it consists of neural 
tissue with neurotransmitters from the brain controlling its 
function. So, developing this bioassay was a very delicate and 
complex process.
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Basically, our theory centered on dopamine production, 
which affects the anterior pituitary by reducing the release of 
a hormone called prolactin.  I began studying dopamine in 
order to create a theory as to why the infected fescue grass 
caused so many problems. On a biochemical level, dopamine 
affects the pituitary by inhibiting adenylate cyclase, which 
converts ATP to cyclic AMP and is necessary for prolactin 
inhibition.  Interestingly, what we saw in all of these horses 
that were grazing on the infected fescue was prolactin 
inhibition, which led to lactation problems.  
We started testing that theory, and I thought, “If I can block 
that receptor up there where the dopamine activates those 
cells, maybe I can reduce the inhibition to allow prolactin 
to be produced normally.”  I started studying D2 dopamine 
receptor blockers for those particular pituitary cells in order 
to find a method to block the alkaloids, and we developed 
the bioassay system to see if those alkaloids were actually 
being blocked. This took us about three years.
I then began screening drugs to reduce the affects of the 
alkaloids and the dopamine, and we found a drug called 
domperidone did just this.  With this drug, we successfully 
blocked the dopamine and alkaloids in vitro.  We tried other 
drugs, of course, but decided to stay with this one because 
it did not cross the blood-brain barrier.  Drugs that do cross 
this barrier, which are often used as psychotropic drugs, had 
too many negative side effects and safety issues. Liability-
wise, we could not put a drug like that on the market 
because horse owners would have eaten us to the bone by 
lawsuits.  So, we stuck with domperiodone.
We moved to the field very quickly with this drug. Normally, 
when you develop something in the lab it kind of blows 
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up when you take it out into the field to test on actual 
animals, but that was not the case with domperidone. In 
1991, we took it into field testing, and I began feeding the 
mares originally on the control pasture the toxic fescue in 
combination with oral doses of this new drug.  I started them 
on this regimen 30 days prior to their expected foaling and 
continued until they foaled.  
At the level we initially administered the drug, the mares 
started looking like they were getting toxic again, so we 
doubled the dose we initially gave them.  Eventually, when 
we adjusted the dosage to 1.1 mg per kg of body weight, 
the mares started responding.  We were lucky, too, because 
the drug worked during the first study it was used, which is 
rare. The mares that were not receiving the drug were still 
having problems, but we started seeing that the mares on the 
drug foaled on time, had healthy foals, and were lactating, 
and they did not have those thickened placentas.  The drug 
eliminated every one of the symptoms related to the toxic 
grass because it blocked those receptors.  
For about eight years, I did not release the fact that the drug 
also had another effect, which we call the alpha-1 receptor 
antagonist effect.  We kept it quiet because if we released 
this information, we knew that the big drug companies 
might copy it.  So as far as I let on, the drug was just a D2 
dopamine receptor antagonist, which was how we initially 
classified it.  However, the fact that it was also an alpha-1 
receptor antagonist became very important in solving this 
problem.   Actually, it was kind of a miracle—a lot of it was 
just very fortunate.  
After our success with the horses (about 24 in all), we started 
working with beef cattle.  To make a long research story 
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short, the drug worked great on beef cattle as well. We did 
studies on cows, calves, and steers and found that the drug 
eliminated the toxic effects of the infected fescue grass in all 
of them.
The next problem we faced was with the Food and Drug 
Administration. It cost us about $6,000,000 to clear the 
drug for horses; however, for cattle, it would have been about 
$40,000,000 to develop all of the data the FDA wanted for 
cattle, and that was if we did not run into any problems. 
Only a big company could have afforded that. The reason for 
this large expense is that the FDA has to be sure that none 
of the drug residue will harm humans if they consume meat 
from cows on the drug.  This was not an issue for the horses, 
though, because they are non-food animals in the United 
States.  
In 1991, we felt like we had a strong enough solution to the 
fescue toxicosis problem, so we disclosed our findings to 
the patent committee at Clemson University. The patent 
process takes some time, so the patent for domperidone was 
not issued until 1994.  The patent covered domperidone 
use for all mammals, not just for horses, and even included 
humans.  Some parts of the patent also included the use of 
ergoalkaloids as well.
In 1994 and 1995, I tried to sell the patent to a few big 
companies that had the wherewithal, knowledge, and money 
to clear the drug.  Even though a few companies showed 
some initial interest in the drug, no one ever really bit into 
it, so I was really discouraged.  I felt like I had something, 
so I came back to the university after all that and said that 
I wanted to buy my patent back. In other words, I wanted 
a contract that said that I had the right to market my 
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technology.  The university did not make it easy, but they 
eventually granted me the right to have my patent and told 
me that I could spend that $6,000,000 to develop the drug.  
As I tell people, I knew then that I was like a termite eating 
a cross tie, but I did not realize that the cross tie was filled 
with creosote.
I signed an agreement with the university to develop the 
technology and established a startup company, Equi-Tox. 
We also hired a consulting firm in Dallas, Texas that had 
people who knew how to clear drugs.  The whole process 
is extremely complex; a person can spend a lot of time 
and money and still have his study rejected—I am personal 
proof of that.  Two of my studies were rejected, but we 
eventually went to the Center for Applied Technology at 
Clemson University (they call it the CAT Center) and started 
developing the drug.  
The process to get a drug accepted by the FDA is 
multifaceted.  We had to prove the safety and efficacy of the 
drug and go through what they call “good manufacturing 
practices,” or GMP, for short.    By far our biggest challenge 
was finding the funds to keep the process rolling.  Even 
though it was kind of tough, the research was great: we 
worked hard; it was fun; and we were doing something no 
one had ever done before, but clearing it through Food and 
Drug was a challenge! That was when we only slept two or 
three hours a night trying to figure out how we were going to 
generate all of the funds to keep the process moving along.
As we were in the clinical efficacy stage of this process and 
were trying to get approval for the drug under clinical testing 
out in the field, we got a call from a large horse farm close 
to Washington D.C.  Apparently, they learned about our 
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research because I had given some presentations about our 
work.  They said that they had exactly the problem that I 
described and that they were losing mares and foals after 
having paid hundreds of thousands of dollars for breeding 
fees.  It was a financial disaster for them as a thoroughbred 
farm.  
I told them that we could not ship the drug because we were 
restricted, and they responded by saying “Well, let us see 
if we can do something about that.”  I guess they knew the 
right people, being located near Washington, D.C. because 
not long after that, I received a call from the FDA saying that 
I could go ahead and ship the drug to some of those horse 
farms because there was no alternative therapy. So, through 
this unique process, we were able to start shipping our drug 
and generating a little income to keep the research going, 
which was all under FDA regulations.
In 1999, we completed a new facility for Equi-Tox because 
the CAT Center was not up to GMP standards; it did not 
meet all of the requirements that the FDA wanted for a drug 
manufacturer, so we had to build our own facility.  It is an 
office complex with a manufacturing facility in the rear, and 
we built it like a horse barn to reflect our products.
I now have nine patents.  We developed various aspects of 
the drug in the States and in other countries.  In December 
1998, the initial patent for the drug was approved.  Then we 
started noticing that most mares, whether they were on the 
infected fescue or not, began rebreeding better after being on 
the drug. We did some control work and eventually patented 
a method for promoting ovulation, parturition, and lactation 
in mammals.
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We also got patents that approved the drug for laminitis, 
which improves blood flow to the foot (which is important 
for horses) and for ease of parturition in pregnant mammals.  
We hope that someday women will also be able to take 
this drug to ease the labor process because it seems to 
make laboring and breastfeeding much easier.  Anyway, I 
hope to develop this drug further in areas related to easing 
parturition.
We also received international patent protection and cleared 
the drug in Australia for follicular growth, which is related to 
ovulation and reproduction.  We are currently in the process 
of clearing it in New Zealand, Canada, and then several 
places in Europe as well.
So in summary, we had to form a lot of partnerships and 
a lot of contracts with different companies.  In 2000, we 
signed a marketing agreement with the Bayer Corporation, 
a German-owned company who was very interested the 
drug. However, things did not work out with them, and 
we eventually dropped the contract. Currently, we have a 
contract with a company in India called Reddy-Cheminor 
to synthesize our drugs.  Of course, the work they do has to 
be done under GMP synthesis, so they filed the GMP under 
what we call the drug master file, which was approved. 
We also hired a lab in Indiana, a human pharmaceutical 
company, to complete all of the GMP requirements in 
the United States, and we now have a new contract with 
a company out of the United Kingdom called Dechra.  
They are the largest veterinary pharmaceutical company in 
theUnited Kingdom, and they wanted to develop new drugs 
in the United States.  So, they bought our technology, nine 
patents, and all of the FDA material that I developed over 
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the years.  Essentially, I sold this drug to another company; 
I received some upfront payments, and I will get royalties. It 
should be marketed under their brand name next fall. 
Interviewer
Has Equi-Tox been completely self-funded?
Dee Cross
Now which comes first, the egg or the chicken?  If I knew 
what I know now, I would have taken investor capital and 
cleared the drug quickly because we had a lot of people who 
wanted to buy stock in the company, but at that time, we 
elected not to. So, Equi-Tox is wholly owned by me and my 
wife; we financed it and have never sold any stock.  
Luckily, I have rental property and own a little bit of land, 
so I was able to borrow money against my equity to start the 
company. Then we got a break with the FDA because of the 
demands from the horse farms and their desire to use the 
drug.  This demand enabled us to develop the drug under an 
investigational number and ship it out to these horse farms, 
which gave us the funds to keep the research running on 
track.  Now, we are a debt-free company that nobody owns, 
even though Dechra now owns our technology on this one 
drug.  
However, we have developed 150 other programs for 
specialty products, and we have accounts with 5,000 equine 
clinics in the United States.  I had to be able to create 
a profit in order to keep the company going, so I had to 
become profit-minded, but the best part of this whole process 
was that we solved a major problem in the animal industry. 
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We also had the opportunity to educate many students who 
were then able to get good jobs because they were associated 
with this research.  Another really great benefit to this work 
is that every large animal veterinary clinic in the United 
States now knows where Clemson is. Even though we do not 
have a vet school here, every veterinary pharmacology book 
published recently has our research about fescue toxicosis in 
horses, domperidone, the dosage, the effects, and so on.  So, 
our work was about solving problems and about creating a 
good reputation for the university.
In order to create this company, I really had to learn how 
to build in the business world.  Believe me, when you walk 
into a large company and say that you are a professor, those 
entrepreneurs will pick your bones.  Luckily, we did not sign 
any contracts early on. Generally, the big companies will start 
out a deal with a sucker contract just to see how vulnerable a 
person is.  I hate dealing with contracts, but it is a necessity; 
you just have to learn how to play the game.
Interviewer
You mentioned that when you had the technology you first 
went to a larger company, and they turned you down. What 
is your speculation as to why they did not go with this drug?
Dee Cross
I pushed it a little bit for cattle initially with Elanco, but they 
were not interested in horses.  The reason for this had to do 
with a lawsuit against them relating to a drug they developed 
for cattle; some horses ingested it unintentionally and died, 
so they just did not want to deal with horses.
As for the other large companies, I think they screwed up.  
I just do not think they knew what I knew.  It was hard for 
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me to convince them to pursue this technology because, to 
them, I was just a professor from Clemson University, which 
is not even a veterinary school, and I wanted them to invest 
in this drug for a problem that they knew little about, and 
they were not well versed in the technology at that point, so I 
could not convince them.  
Interviewer
What does lack of support mean?  You don’t have to name 
names, but just say what does the lack of support mean? How 
would that come about?
Dee Cross
Probably one of the most motivational forces in society is 
jealousy.  You get somebody jealous of you, and you have a 
problem.  Now that I am retired, I can talk about this. When 
you are outdoing some of your peers who think of themselves 
as super-scientists, sometimes you create some friction, and 
then you start seeing little roadblocks being thrown out 
there.  I had to learn how to deal with that; I had to be 
tough and smart.
Interviewer
What about your role as an academic?  It might appear 
that you were focusing on commercializing a technology 
rather than on publishing in academic journals.  Was this a 
problem for other faculty in your department?
Dee Cross
Yes, that is the big argument.  Fortunately, I was able to 
publish as we went along and still protect the patents because 
I did a lot of the patent work later, away from the university, 
even though we ran it through the university patenting 
office.  That is a potential problem, though.  
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First of all, look at the students who came through this 
program; they are very successful; they got good jobs; they 
learned a lot; and their data was published.  So it is a pretty 
hard argument, but in some cases it is valid I guess.  There 
is a proper balance; you cannot go in just one direction. The 
university is a complete system with all facets, and the higher-
ups want faculty to develop technology.  If the university had 
not offered me the opportunity to develop the technology, I 
probably would have just piddled along and never done this.  
That being said, I figured that if I patented, I would get some 
kind of reward out of it.  Then later, when no one would 
buy the drug, I figured I would try to gain these rewards by 
negotiating a contract with the university because I knew I 
had something. Now, the atmosphere is better because we 
have a research foundation and ways to protect those people 
who have technology that needs to be developed.   
So had that other argument won, you know what would be 
the result?  There would still be a huge problem in the horse 
industry; we would still have mares and foals in pain and 
suffering.  It was an economic solution as well.  One farm 
told me that on one foal, we saved them about $1,500,000 by 
treating one mare, and it cost them just $75.00 for the drug.  
There are a lot of people I need to thank for helping 
me through all of these little roadblocks.  The Clemson 
University administration who supported me; the Director 
of the South Carolina Experiment Station; the then-Director 
of Technology Transfer, Bob Gillan; Ed Page, who is now 
retired; Steve Chapman, the University Attorney with 
Patents and Technology; and Vincie Albritton, who is now in 
charge of Technology Transfer. 
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If it had not been for these people, I would have quit, 
but they kept saying “Keep going.  Keep going.  We are 
supporting you.”  Because I had some support up at the 
higher levels, I felt like I was okay.
Now, we are treating all kinds of animals. As one 
veterinarian said, “This drug will put an udder on an anvil,” 
so we can help a lot of animals with it.  We are treating 
dolphins, camels, alpaca, elephants, rhinos, apes, sheep, 
goats, and a number of other species. Now, we are even 
developing several products for dogs.   Even though we are 
going to give up our main drug, we plan to develop other 
things at Equi-Tox, and dogs are one of our biggest targets. 
Interviewer
Are there any adverse side effects of the drug that you know 
of?
Dee Cross
Not that we know of.  We are actually repeating the 
safety study right now.  It is the hardest study I have ever 
done in my life. I had to repeat it because the first study 
did not meet all of the GLP, or the “good laboratory 
practice,” requirements.  So, we are repeating it with some 
veterinarians in Tennessee.  The first study was good; I just 
did not have all of the knowledge that I do now, so I did not 
get all of the checkboxes right at first.  
However, on our label it will say that the drug can cause 
premature lactation.  If a mare is not ingesting much infected 
fescue and she overloads with the drug, she may start leaking 
milk.  However, that actually turned out to be an advantage 
for us.  Currently, about 25-30% of our business is from non-
fescue mares that are not lactating well.  If an owner knows 
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that his mare is not going to lactate, he can start her on the 
drug before parturition, and she will be flowing milk by the 
time she foals (if she is capable of lactating in the first place).  
Some farms start mares on the drug right after foaling if they 
see that the horses are not lactating well.
The label will also say “Do not administer to a horse that 
has an intestinal blockage due to colic” because the drug 
stimulates the gut. If there is a certain kind of blockage in a 
horse’s gut, the drug can increase the pain level.  So those are 
the two safety issues.
I should mention that for safety’s sake, every drug we make is 
administered as a prescription through veterinarians.  We do 
not ship to veterinarians’ clients unless they ask us to.
Interviwer
How do you administer the drug to horses? 
Dee Cross
We started out with a molasses carrier for the drug; it worked 
great, and the horses loved it, but the FDA said it looked 
like we may be getting a little settling of the drug. We did 
not think this mattered because we gave the horses an entire 
oral dose, so they were getting the proper amount of the 
drug regardless of any settling. But, the FDA argued that 
the molasses may not be the same volume if it is 100 degrees 
versus 20 below or something like that, so we had to repeat 
the GMP process.
I ended up putting the drug in a carbopol parabens polymer 
and made a gel to suspend it.  Now we have a five-dose 
syringe with a dial-a-dose mechanism: just turn the dial, 
the the drug comes out, and there are four doses left.  Then 
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we had to prove through GMP that there were no safety or 
accuracy issues with the syringe.  
We also had to do stability studies on the drug, which took 
two years. We had to assay all of the other components in 
the syringe as well, like the parabens, the methylparabens, 
the apple flavor, and everything else we put in the mixture. 
Then we had to do batching.  We started with 10% batches 
and proved that everything was okay with them. Then, we 
had to scale up the batches to manufacturing levels.  
Then, the facility had to meet all kinds of cleanliness 
requirements: the floors, drains, air, water, etc. We had to 
test our water and run bacterial analysis on it, and then we 
had to do the same thing for our syringes, and on and on. 
Inspectors can always find something to shut a plant down.  
The FDA is not rational.  For example, our drug was used on 
non-food animals, and it showed no safety problems. Before 
it was cleared, we treated 100,000 mares with no negative 
results. The FDA told me once, “We know the drug is safe.  
You would have been sued and put out of business if it was 
not safe,” but they still put us through the same requirements 
as those for a human drug except for tissue analysis.  That is 
why the whole drug-making process costs so much and takes 
so long.
Interviewer
I was just wondering if there a chance that this drug will be 
marketed to women?
Dee Cross
Yes, actually there is.  Our daughter-in-law had her baby at 
the hospital in Charleston.  While we were visiting, I asked 
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them if they had ever heard of domperidone, and they told 
me that they were actually using it now.  
But here is the bottom line: big pharmaceutical companies 
and the FDA work together. They do not like it when little 
companies come along because we are not familiar with the 
drug-manufacturing process, which costs them a lot of time. 
Big pharmaceutical companies make the process go much 
faster, which justifies their positions.
Interviewer
How were the doctors getting the drug?
Dee Cross
They were not getting it from us.  We stayed away from 
humans for liability reasons, but they read our research and 
began getting the drug through formularies.  A formulary 
is a very important part of the pharmaceutical industry.  
The FDA hates them, and big pharmaceutical companies 
hate them, but when you have a unique problem, you need 
a special formulation to solve that problem.  A doctor can 
prescribe a pharmacist to make him that formulation for his 
patients, and that was how domperidone was being used.
Interviewer
Did companies look at the patent to see what the 
formulation was?
Dee Cross
We have had so many violations of our patents, and I have 
hired patent attorneys and sent letters.  We would send the 
formulary makers threatening letters saying that we were 
going to sue them, but then I began to look at it from a 
different standpoint: we would have needed about $100,000 
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to file a patent lawsuit, and if the company we were suing 
was bigger than us, they could have outlasted us and busted 
our patents.  We have wholesale black marketing of the drug 
going on, but I have turned that over to Dechra now.  But 
they say that it is a sign that you have a good drug when all 
the thieves come out and start selling it.
Interviewer
What kind of patent do you have?
Dee Cross
We have a use patent, not a formula patent, so we could 
not protect against the formulary development.  However, 
I patented the drug in terms of all of the methods for 
administering it, and I have nine patents covering everything 
I could think of in terms of the drug’s use.  It is a matter of 
getting in the court with lawyers and everything, and at my 
age, I have decided that I am going to take a buyout and let 
the big pharmaceutical company deal with this problem.  So 
that is what Dechra is doing now; we transferred all of our 
files on patent litigation to them. That is what happens with 
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2007 at the Clemson University Renaissance Center.  Since this 
interview occurred, the company has hired eight full-time employees 






So the question I would like to begin with is how did you 
develop Selah Technologies?  How did it happen?  You can 
start anywhere you want.
Michael Bolick
In my youth I was awarded a scholarship to attend a Hugh 
O’Brien youth leadership conference.  The conference 
celebrated our nation’s free enterprise system.  My interest 
in running my own business took root in this setting.  After 
earning a degree in Chemical Engineering from North 
Carolina State University, I accepted a job offer to work 
on a startup team for a Japanese-owned specialty chemical 
manufacturing plant in Chattanooga, Tennessee. I really 
enjoyed the experience of helping to design the facility, 
specifying and purchasing equipment, tracking construction 
and equipment installation, writing operating procedures, 
hiring and training people, etc.
In 1997, I was blessed with an opportunity to move 
to Greenville to help start up a Swiss-owned active 
pharmaceutical ingredient (API) manufacturing plant.  At 
that job, I held more responsibility, but the process was 
basically the same: a grassroots startup of an advanced 
materials manufacturing plant.  Once again, I thrived in the 
startup setting.    
Over those past 15 years, I enjoyed a successful and 
satisfying career.  But about two years ago, I realized that 
I could no longer accept the thought of continuing in the 
same direction.  I considered looking for another startup 
opportunity, but this would most likely require relocation, 
which was not an attractive option.  I have three children, 
Perry (14), Connor (12), and Madison (9), who have grown 
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up in the home we built here in Greenville. The last thing I 
wanted to do was move again for a new opportunity. 
Coupled with this was the realization that I really wanted 
to finally reach for my dream of building my own company. 
My wife Sheelah was very supportive during this process. 
We talked and prayed together and decided to start a new 
business.
Once we had a plan in place, I reached out to a group of 
more experienced business people in the area.  I was very 
fortunate to have a group of people who were willing to 
block out some time and listen to me.  When we sat down, 
I laid out the situation and asked for input.  My side of 
the conversation usually went something like this:  “I am 
planning to make a transition to start my own business.  I 
need to make a break.  I need to make a change, but I do 
not want to do it in a rush.  I want to do it in an organized 
manner.  Do you have any suggestions of how best to 
proceed?”  I got a lot of really good advice and thought 
starters from this set of meetings.   
I looked at a number of options.  I looked at buying 
franchises or existing businesses.  I have friends who 
made the transition from corporate life to entrepreneurial 
ventures.  One started a bread-baking business.  Another 
started an attractive high-end butcher shop.  I seriously 
considered that route, but I kept coming back to my desire to 
start something that would allow me to leverage my advanced 
materials manufacturing background.  
At about this time, I heard about the InnoVenture 
conference here in the Upstate.  The idea behind the 
conference, as I understood it, was to mix inventors, 
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entrepreneurs, and investors together for collaboration and 
idea sharing.  I took two days of vacation and attended 
InnoVenture 2006, consciously looking for an opportunity 
with my mind wide open.  Several people were praying for 
me to find what I was looking for, as my search had not 
yet borne fruit.  I joined them in asking for guidance and 
wisdom.  Most of my prayers were along the lines of “If there 
is something here, please help me to hear it; help me to 
recognize it.”  And I will tell you there was a really exciting 
vibrancy to the community that was there.  There were a lot 
of opportunities to consider.  Unfortunately, to my chagrin, 
still nothing clicked for me.  
That is, until I saw the presentation by CURF (Clemson 
University Research Foundation) representative Matt 
Gevaert. Matt presented on a technology that had been 
invented in Clemson’s advanced materials laboratories. 
The technology was called “carbon dots,” short for carbon-
based quantum dots.  Quantum dots are light emitting 
nanoparticles that are very promising for a broad array 
of applications, including cancer detection and other life 
science applications.  The main point I remember hearing 
was that this new technology was based on carbon rather 
than on cadmium or other heavy metals.  A carbon-based 
quantum dot was expected to be less toxic than heavy metals 
and would, therefore, have a compelling advantage in the 
marketplace.  The market was growing rapidly even without a 
heavy metal quantum dot alternative.  This really caught my 
attention.  
I remember it was not a very long presentation.  Afterwards, 
I went out to the CURF booth and spoke with Matt Gevaert 
and Vincie Albritton.  I handed Matt my transition card with 
my personal contact information and said, “I want to start 
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my own business, and this technology looks very attractive 
to me.”  About three weeks later, I signed a NDA—Non-
Disclosure Agreement—and got a chance to really dig into 
the technology. 
As I said earlier, for the last ten years I have worked as an 
executive for a contract research and manufacturing firm 
servicing the pharmaceutical industry.  Sometimes we would 
make APIs for a drug that was already on the market. More 
frequently we produced materials that supported clinical 
trials.  This means that we made small amounts initially and 
then scaled up production volumes as a given API was taken 
to larger and larger clinical trials.  Our home run was to 
make an API for a company from the clinical trials through 
launch and into the market.  This experience provided me 
with the ability to look at this new technology and see that it 
could be very scalable.  
Near the middle of May 2006, I formed a company called 
Selah Technologies, LLC (www.SelahTechnologies.com). 
The name “Selah” means “to pause and reflect on what has 
been said.”  Selah Technologies obtained an exclusive option 
to negotiate for the technology.  Now, this option is not the 
actual license; instead, it is a period of exclusivity to conduct 
due diligence to determine the value for the base technology 
and to develop a commercialization plan.  This period is 
effectively the start of the business planning process.
Around this time, there was a paper that was published 
in the Journal of the American Chemical Society (JACS).  
The paper described the implications of a carbon-based 
quantum dot and referred inquiries back to Clemson. Quite 
a few people read this paper and contacted Clemson and 
the inventor.  Many of these contacts were referred on to 
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me.  Some of the inquirers came through, and I took the 
opportunity to sit down with them and try to evaluate how 
we could collaborate to commercialize this technology.
So, as the summer progressed, I realized that we had an 
outstanding opportunity on our hands.  I entered into 
negotiations with Clemson to obtain the license not only 
for the carbon-based quantum dots but also for another 
technology that allows enrichment of carbon single-walled 
nanotubes.  Both of these advanced materials technologies 
are referred to as “platform technologies.” 
A platform technology has great potential in a number 
of vertical markets.  To be able to license two platform 
technologies is a blessing.  It means that we have more than 
one arrow in our quiver.  On the other hand, an abundance 
of market opportunities can be a siren song that keeps the 
entrepreneur from focusing on a particular “go-to-market” 
strategy.  This lack of focus is sometimes referred to as trying 
to “boil the ocean.”
In September, we concluded negotiations, and Selah 
obtained a worldwide exclusive license to develop and 
commercialize both carbon-based nanotechnologies.  
I have to tell you that Clemson was very supportive, and 
they were great partners in the negotiation.  CURF was a 
good steward of the technologies invented at Clemson.  The 
CURF representatives really pushed me to demonstrate that 
I had the ability and a sound plan to move into the market. I 
also think Clemson and CURF were interested in engaging 
with the entrepreneurs in South Carolina to help transition 
our state to a “knowledge-based” economy.
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Once Selah had the exclusive license on both technologies, 
I was able to kick into full gear.  I took advantage of the 
preliminary contacts that we put in place to start what we 
considered to be our strategic intent.  This intent was to 
build relationships with major multinationals that already 
had ongoing nanotechnology research programs.  
We are bootstrapping the business right now: building value 
in the business before we seek outside investment.  This is 
a challenge to balance properly.  I see myself as a steward of 
this opportunity set.    
So, in a nutshell, that is the story behind how Selah was 
developed.  We were blessed to have a number of potential 
industrial partners, and customers responded very early and 
very positively to Selah’s technologies.  I cannot get into 
the specifics just yet, but these interactions have been very 
encouraging.
I will conclude by mentioning that in January, our Chief 
Technology Officer, Dr. Andrew Metters, joined us from 
Clemson University.  Before joining our team he was an 
assistant professor at Clemson. It was decided that before he 
joined the project full time, he would finish out a previous 
commitment to his students.  He had two students who had 
not yet defended, so he worked on a part-time basis for Selah 
until just recently.
And then, in March of this year, Ken Morgan, our Chief 
Operating Officer, joined us as well.  So we have the 
technology in place; we have potential partners and 
customers encouraging our growth; and now we have a core 
team of motivated folks that are all pulling together.  Selah is 
blessed with a lot of momentum.
ACORN 69
Interviewer
So, let’s start at the beginning in terms of your background 
knowledge.  It sounds like the expertise that you brought 





What about your background in marketing?
Michael Bolick
Marketing and finance are two areas that are the least 
familiar to me.  In my career, I learned that everyone 
involved in a startup has to wear a lot of hats.  I also learned 
the lesson of trying to take on too much by myself.  Finally, 
I learned to delegate responsibilities, to empower others, and 
to share the load. 
I spent my entire career serving customers in the advanced 
materials manufacturing business.  I know what it means to 
work with customers: day in and day out for both long-term 
and short-term projects.  Making sure that you communicate 
effectively is the key to doing business.  
You learn how to discover and be sensitive to what your 
customer’s real needs are, and you communicate with them 
to ensure they are always fully informed.  It is important to 
establish a relationship based on trust and ethical dealings.
So in summary, I have a solid set of skills that will be directly 
translatable.  There are also some areas where for which I do 
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not have experience, but I am gathering an extended team of 
associates and advisors that will fill in the blanks.  
I believe that without counsel, plans fail, but with many 
advisers, they succeed.  That is not my concept; it is from the 
Bible (Proverbs 15:22).  As you broaden the group of people 
who give you advice and counsel within a certain context, 
you awill make your decision making more effective.
Interviewer
Could you elaborate on some of the kinds of advice you have 
been given to help make the business become a reality?
Michael Bolick
Well, I have to admit that a few of my friends thought I 
was going down the wrong road.  They would say “You are 
making great money.  You have an excellent job.  How can 
you walk away from such a successful career?  What are you 
thinking?”—that type of thing.  
I listened to the whole range of perspectives, but I knew 
it was time to make a change.  I believe that if you are not 
careful, it is very easy to float along in the security of a larger 
company.  Do not get me wrong, corporate politics and 
layoffs are not much fun, but there is a set of rules by which 
most corporations and people play.  Lifetime employment 
does not really exist anymore from my perspective.  Typically, 
you are going to have to keep going and build a career with a 
series of companies.  
In this setting, however, you do not have the opportunity to 
influence the direction of the company as readily as you do if 
you start something with a team of people and you are right 
there at the center of it.  
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In any event, there were a few people that really made a 
difference in my decision. One really good friend, who has 
his own business here in town, encouraged me to seize the 
opportunity to realize my dreams.  He said, “Look.  I know 
you.  If there is anyone I know who should run his own 
business, it is you.”  
I said, “Well, you know...”   
He said, “No, you are not hearing me.  You need to start your 
own business.”  
Once I psychologically made the leap and said “Okay, I can 
accept the fact that I am taking a huge risk and that it may 
not work out,” I realized that I was in it for the long haul.  
I have great faith in God’s providence, and this gave me 
courage.  At the end of the day, I knew that I had no idea 
whether or not Selah Technologies would turn out to be a 
success, but I was convinced that I needed to make a go of it.
At this point, I realized that I needed to broaden my advisor 
base.  I started looking for serial entrepreneurs in the local 
community who would be willing to guide me.  I was blessed 
to find several people, who were willing to stop, listen, and 
give me counsel.  Most of these individuals did not have 
advanced materials manufacturing experience, but each had 
entrepreneurial start-up experience, including successful 
exits.
I said, “Okay, what do you think of this idea?”  I laid out the 
basic technology information and the market analysis that I 
had compiled. I picked their brains. I asked “How would you 
approach this?  What do you think I should do?” I spent a 
couple of months bouncing ideas off people. 
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And the responses I got were along the lines of “You need 
to read this book; you need to look at this opportunity; etc.”  
I was introduced to the concept of how a lifestyle business 
compares to a growth-mode business. Other issues were 
pushed to the front burner: “What kind of financing do I 
need to have?  Where am I now in the process?  What do I 
want the company to be when it grows up?” 
I had several mentors reinforce the idea that with a 
technology-based business, you have to push to get your 
product to market in a focused manner with an eye on the 
next big thing coming along behind you.
I was fortunate to have many introductions from 
InnoVenture 2006.   I also reached out to the Greenville 
Chamber of Commerce.  I was introduced to and joined a 
group called NEXT at the Chamber of Commerce, which 
focuses on creating new entrepreneurial infrastructure in the 
Greenville area.  I engaged with a number of entrepreneurial 
support organizations available in the area.
Interviewer
At what point had you written a business plan?
Michael Bolick
I had an early draft, but it needed improvement.  I was 
fortunate to learn this before I needed to raise money.  You 
do not want to go to Angel or institutional investors unless 
you are well prepared.  You only have one chance to make a 
first impression.  People will establish perceptions about your 
competence based on your initial pitch.
On the other hand, I was also aware of the danger of getting 
so preoccupied with establishing an infinitely detailed plan 
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that you forget the reality that things will vary from your 
plan.  You have to be able to adapt.  Practically speaking, 
making projections longer than three years is extremely 
difficult.  Then there is the balance between projecting the 
exciting future you see and establishing realistic expectations 
for a number of stakeholders.  
I finally settled on a business plan that is tied to critical goal 
categories that then flow out to action items for our team. 
We plan to keep an eye on the plan and to adapt and update 
it as needed to take advantage of changing market conditions 
and opportunities. 
Interviewer
So at this point, are you self funded?
Michael Bolick
Yes.  My wife is my partner.  When we started the business, 
we reviewed the opportunity and our financial situation. 
Then we decided on an amount of money we thought we 
could afford to invest.  At that time, we set out milestones to 
gauge our progress. 
Looking back, we are pretty close to that original set of 
expectations, but I have to admit that in the planning, I did 
not include all of the other expenses that I had historically 
paid for with my prior paycheck.  I knew these expenses were 
still going to be there, but I think I just blinded myself to the 
problem.  
Every successful business person I know tells me that “cash 
is king.”  I am reminded that if you are not extremely careful 
and you do not plan in a safety factor beyond what you think 
is likely to happen, you will end up running out of runway 
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before you can take off.  Fortunately, because my wife is an 
excellent partner and my best friend, we have been able to 
get through these types of things and not “sell out early” to 
the detriment of our family or the company.  
Our goal is to build an advanced materials manufacturing 
business selling to the global marketplace from the Upstate 
of South Carolina.  I see this as an opportunity to step in 
and engage as part of our state’s transition to a knowledge-
based economy.  We are fortunate to be in the right place at 
the right time to do good, solid, ethical work during a rising 
tide of opportunity.  We are so blessed to be here.  This is 
a wonderful community.  The people here are very friendly. 
There are a lot of people moving in from other parts of the 
country because they want to be part of this great thing we 
have going on and where our state and our region is going.   
Some people have said that the transition to a knowledge-
based economy is the end of manufacturing in South 
Carolina.  I respectfully disagree.  Our community knows 
how to do manufacturing.  On the contrary, the transition to 
a knowledge-based economy is a means provided to enable us 
to save and grow manufacturing in South Carolina.
Interviewer
How did you do your due diligence when you had the option 
to explore the nanocarbon technology?
Michael Bolick
That is probably the most challenging part of this whole 
process because of the concept of technology transfer.  I 
have lead teams doing technology transfer from a number of 
customers to our laboratories for more than a decade in the 
pharmaceutical industry.  Every time you transfer something, 
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there are going to be problems.  Every time you scale up, 
there are problems.
The question is how many problems will there be? Hopefully, 
if you have been down a given path a few times, you have 
the luxury of experience.  Recalling problems similar to 
mistakes that were already made, you try not to make the 
same mistakes again.  Regardless of past experience, when 
you have chemistry involved and you try to scale up, you will 
likely encounter things that could not be anticipated.
So we are looking at technology that has been proven on a 
research scale— in a very small vial, so to speak—in a research 
laboratory.  We now need to extrapolate the process to a 
manufacturing plant.  I would have been fooling myself to 
think that I could look at that and see every challenge that 
we might encounter.  But what I was able to see, what I saw 
right off, was that there was not some multi-million dollar 
piece of capital equipment that would be necessary to begin 
production.
I looked at the complicated, expensive, and inconsistent way 
that the current market leaders are making heavy-metal-based 
quantum dots and compared this to what had been invented 
in the Clemson research laboratory.  Our process is robust 
and highly scalable.  It is a very elegant answer to a not so 
elegant problem.
At the core of our product, no pun intended, we have carbon 
instead of cadmium.  I mean we are made from carbon.  
Organic life forms are made from carbon.  I drink water 
every day from a carbon-based water filter.
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I want to point out that we will not just assume that there are 
no negative health effects from a carbon nanoparticle, but 
I am confident from looking at it initially that the potential 
problem is greater with cadmium than with carbon.  
So, I am trying to follow up on all of these things.  My initial 
thought was that this looked like a no-brainer for a base 
technology, possibly not for every application, but there are 
going to be places where the carbon dot will be a very well-
received alternative to the heavy-metal-based quantum dot.  
I interacted with the researcher at Clemson University, 
a brilliant man.  I received assurances from him that he 
would be a partner with us to transfer the technology out of 
his laboratory into our laboratory.  Those assurances were 
fundamental to my decision-making process.  I was brought 
up to believe your word is your bond.  To have this fellow 
indicate a willingness to step up and help was very, very 
important in my decision-making process.  
Now, at some point you have to stand on your own two 
feet, which is why I looked for someone who had Dr. 
Metters’ qualifications—not only the qualifications from an 
academic perspective and a technical perspective but from a 
personality standpoint.  I needed to grow the manufacturing 
capacity and scale up the process.  We do not need to come 
up with a different type of dot; I just need to make this dot 
be as good as it can be.  
Although that happened after we had the license, it is 
still part of the due diligence process because I am still 
funneling money into the business.  I learn more on a weekly 
basis about the technologies’ potentials, and fortunately, I 
continue to become more confident and thankful rather 
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than more concerned.  I feel more and more excited rather 
than more scared.
Interviewer 
Please talk about the specific potential applications of this 
technology.  
Michael Bolick
Well, I have to be careful with this.  The nanotechnology 
field is experiencing an intellectual property (IP) 
blizzard right now, so I have to be wise about what I 
publically disclose.  Several years ago, there was a bit of a 
nanotechnology patent gold rush.  Patent applications were 
filed claiming very fundamental things. In some cases, 
patents were issued that had overlapping claims, and some 
patents had been issued that confused the playing field.  
Some of that is getting shaken out now, but when we talk 
about taking carbon dots into a particular application, 
you have to know that each one of those ideas represents a 
potentially different intellectual property position.  Each case 
might need to be protected by a patent application before 
being publicly disclosed.  
What we are trying to do now is share ideas about the 
potential of our technology without giving away the farm. My 
younger son, Connor, gave me an idea for one of the ideas 
that we are sharing openly: carbon-dot-enhanced paints.  The 
idea is to make a paint that glows when you turn on a black 
light in a dark room. Imagine painting the walls of a play 
room or media room and turning on a black light.  The walls 
will glow with a fantastic electric blue.
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There is no paint on the planet right now that will do that! 
This has never been considered by any kind of quantum-
dot manufacturer because no one would want to pay for 
cadmium-based quantum-dot paint, not to mention the 
environmental issues with the disposal of a cadmium-based 
product.
Well, one readily available excitation source for carbon dots 
is the black light.  The excitation source provides the electric 
blue wall color.  We could also change the wavelength of the 
excitation source to, in turn, change the color of the wall. 
What color do you feel like today?  
This phenomenon is called photoluminescence.  Carbon dot 
electro-luminescence is another exciting option we want to 
investigate.  Scientists have already proven that heavy-metal-
based quantum dots will emit light when exposed to an 
electrical field.  With this technology, you would no longer 
need the black light; your whole wall would become the light 
source.  
One of the most exciting areas to employ carbon dots is in 
the life sciences.  The ultimate goal is to use carbon dots as a 
biological imaging agent.  In other words, we want to develop 
a way to use the dots to find biological targets like cancer 
cells as part of a diagnostic toolset.
The first application we are targeting in this area is called 
in vitro diagnostics.  In vitro means the test is being 
performed outside the living organism.  A physician takes 
a sample of interest (such as a biopsied tissue) and places it 
in a Petri-dish-type container.  The physician then applies 
the carbon dots as part of a testing process to determine if 
the sample has cancer cells or some other target of interest.  
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Organic dyes are being used in this market, but these have a 
number of limitations, including a tendency to photobleach. 
Photobleaching occurs when the dye stops emitting light 
after only a very short testing period.  Carbon dots are much 
more resistant to photobleaching compared to organic dyes. 
The other example I have described in a public setting 
involves skin cancer. I recently had a small growth cut from 
the back of my leg.  The doctor told me she wanted to cut 
away only the suspect cells, but it was a bit of a guessing 
game.  She said, “There is a balance between cutting too 
much healthy tissue away versus leaving bad cells behind. 
I am going to send this part off to have it tested.”  I had 
to wait a few weeks before I found out that the test was 
inconclusive and that I had to have more tissue biopsied to 
repeat the test.  Just imagine how many times per day this 
happens.  Fortunately I was only dealing with what turned 
out to be a benign growth on the surface of my skin.   
We are planning to create “point-of-care carbon-dot-based test 
kits” that will allow a doctor to spray a carbon dot solution 
across questionable tissue.  The doctor would then turn on 
a special light in the office to light up all of the bad cells.  If 
there were cancerous cells present, the doctor would be able 
to see them with the naked eye.   So, when the doctor comes 
in to cut out the bad tissue, the margin will be well defined.  
If a doctor does not have to guess at the location of the 
margin, treatment will become significantly safer and more 
effective.
Now, whether the cancer is in a Petri dish or on the surface 
of the skin, medical decisions are being made.  This means 
that any product involved in making a medical decision will 
undergo scrutiny by the FDA.  The FDA helps to ensure 
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that such a tool is safe, effective, and consistent.  This is why 
we are focused on generating data for in vitro diagnostics 
to support an eventual move to in vivo diagnostics: in vivo 
means “in the body.”
Looking out to the most exciting in vivo applications, we 
wanted to enable doctors to use carbon-based quantum dots 
as the imaging agent in full body scans, such as the MRI or 
CT scans of today.   
We have been blessed with a great deal of potential and 
momentum.  I see my primary role as that of a steward of 
this set of opportunities.  We have to watch the cash burn 
rate.  We have to hire the right team.  We must work to get 
the business on its feet and then identify and work with the 
right partners and collaborators.   
Interviewer
Were there problems that you thought would occur that did 
not occur?
Michael Bolick
Well, let me think a bit about that one.  I envisioned a whole 
range of problems potentially occurring.  We could have 
gone out of business.  We could have run out of money 
already.  Thankfully, none of those things happened.  
We could have found it difficult to find outstanding people 
to grow our team.  Instead, we have been blessed to have 
outstanding people interested in joining our team.  People 
are now coming to us saying “we heard about this great 
opportunity.  We want to be part of it.”  It is interesting to 
see that dynamic change. 
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I try not to worry.  I try to plan for risks and then put things 
in place to mitigate those risks.  I work very hard, and then I 
pray for wisdom and positive results. 
Interviewer
Were there problems that you did not think would be 
problems but turned out to be?
Michael Bolick
Yes.  The actual technology transfer into our laboratory did 
not go as smoothly as I had hoped.  We have thankfully 
moved past this problem, but this delay was more than I had 
hoped for.  You know, the plain truth is that God does not 
promise us a guarantee of an easy road to success on this 
Earth.  We are sometimes given adversity to strengthen us.  
During these trials, we have to have faith and keep working.  
That worked for Selah in this case because we were blessed 
to have a group of people that stepped up—both inside and 
outside Selah—to help address the base-technology transfer 
issues.  So, there have been unexpected problems, but again, 
we have been provided with the means to address those 
problems.  For this I am very grateful.
Interviewer
The last question is what advice would you give other 
entrepreneurs considering a technology business?
Michael Bolick
Well, the first thing, the most important thing is to never 
forget that your word is your bond.
Next is if you do not try, you will never know.  I struggled for 
some time before I could finally turn in my resignation and 
walk away from lucrative employment with great job security 
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and a great career path.  I guess you could call that decision 
a leap of faith.  I do not know if we will make this all work, 
but I know with absolute certainty that if I had not given 
this a shot, I would have always regretted it and looked back 
wondering what might have been. 
Unless you can get to strong cash flow early, you are likely 
to need to go out and ask other people for money.   This is 
not my favorite part of the job, but it is a necessary part of 
the job.  Make sure your documents are well thought out and 
clean.  
We are seeing a rising tide of entrepreneurial opportunity in 
South Carolina right now.  If you have the burning desire to 
do this, listen to your instincts.  Do everything you can to 
build the right plan and team, but do not lean only on your 
own understanding; be willing to listen.  If you do, there are 
a lot of people here that will help you.  
Proverbs tells us that a wise man “sees danger and hides 
himself, but the simple go on and suffer for it.”  This reminds 
me that not every idea is a winner.  Some ideas are just plain 
wrong.  A really good mentor will tell you when your idea 
stinks.  
I have had quite a few of those conversations in the last 
year and a half.  Truthfully, I will not say that in every case 
I completely agreed, but I listened, and hopefully I listened 
well enough to make wise decisions as we go forward.  
Finally, remember the difference between a lifestyle business 
and a growth-mode business.  Unless you can figure out a 
way for your technology to be “it” for an extended period 
of time, it is difficult to build a lifestyle business around 
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technology.  You have to be of a mindset that you have to 
grow or die, but remember that you cannot grow so fast that 
you outrun your cash supply.  Focus on these conflicting 
priorities, and you will have a great shop and will grow a real 
business.
I say this last part with a silent prayer in my heart.  We have 
not gotten there yet.  God willing, our team will look back 




Elizabeth Cates is co-founder of Invenca, an advanced materials 
company in the chemical and biochemical separations field. 
Founded in 2007, Invenca emerged from work done at Clemson 
University and is now located in Greenville, South Carolina.  In 
this interview, which was done in July 2009, Elizabeth discusses 
Invenca’s founding, current work, and future goals.  Currently, 
the company’s work centers on developing new materials for liquid 
chromatography and creating cost-effective separation products for 





So, how did your company start?  Where did you begin?
Elizabeth Cates
Invenca got its roots in 2006 when Dr. Brian Morin, my 
cofounder and business partner, went to Clemson to talk 
with Phil Brown at the Palmer Science and Engineering 
Department about some of the work that he was doing. Phil 
introduced Brian to this technology at Clemson that used 
fibers as the basis for chemical separations.
Brian examined the technology and immediately saw the 
utility in it. Then, with a little more research, he realized 
that he could build a pretty successful business around this 
technology and decided to license it from Clemson.  
For this type of work, you really need to have someone who 
understands the chemistry behind the technology. I have 
known Brian for 20 years; we went to high school together 
and have kept in touch ever since, so when he needed a 
chemist for this company, he called me up and asked me to 
get involved.  I came on board in late 2007 and launched the 
company.  
Clemson University has filed several patent applications 
in this area, to which we have an exclusive license.  The 
technology invention is not commercially viable, so we need 
to find the innovations that will make it a commercially 
viable product.  We are trying to find ways to take this 
technology and really make it something that we can 
manufacture commercially to meet commercial demands.
Interviewer
Okay, so what exactly is your technology? 
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Elizabeth Cates
The technology that we are producing is a basis for chemical 
separation. Chemical separation is done in the liquid state. 
So, if you have a mixture of chemicals in a liquid, then you 
can use our technology to separate them. 
The technology itself is called High Performance Liquid 
Chromatography, or HPLC for short. HPLC is one of the 
most frequently used analytical techniques in the world, 
second only to weight measurement and pH measurement. 
It is used every day by thousands of chemists and 
technologists worldwide to measure things like the purity 
of the product that a company is producing, whether that 
is in a pharmaceutical plant or a personal-care product 
like hair spray.  It is used in clinical testing to look for 
disease markers and in drug concentrations in patient 
samples (urine or blood samples typically).  It is also used in 
environmental testing, as a way of determining the presence 
of environmental contaminates and quantifying their 
concentration.  As you can tell, HPLC is used very regularly 
for analyzing the purity or composition of materials.  
On a larger scale, the same principles can also be used for 
purification.  If we can isolate a compound and identify how 
much is present in a given solution, then we can also isolate 
that compound and collect it in order to have a pure sample 
of the compound. 
Chromatography is also one of the primary methods for 
purification of biopharmaceuticals.  Most of the vaccines and 
over half of the drugs in the pharmaceutical pipeline right 
now are based on protein structures, so the technology that 




Are there other companies that do this kind of thing?
Elizabeth Cates
There are a surprising number of companies that make 
products like ours.  The industry itself is about 50 years 
old, so it is a well established industry.  For an industry that 
is fairly mature, there are a surprisingly large number of 
companies.  In a mature industry, you would expect to find 
only a handful of companies present; however, the number 
of companies that are making products in this area is well 
over 200. 
It is a vibrant industry that really loves new products and 
new technologies. The small companies out there really focus 
on creating niche and custom applications and developing 
new applications; that is where Invenca fits in—developing 
new applications.
Interviewer
So, is your product unique as compared to the others, or is it 
just better?
Elizabeth Cates
It is a unique product.  If we look at the HPLC industry 
as a whole, it has historically focused on small molecules, 
pharmaceuticals primarily: things like aspirin or 
acetaminophen.  The technology has evolved around these 
small molecules because they comprise the bulk of the 
current HPLC market.
However, as I mentioned before, the market for biotechnical 
materials is growing very rapidly. Even in this economy, it is 
still seeing double-digit growth, and like I said, more than 
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half of the products in the FDA’s pipeline right now are 
biologically-derived materials. 
As it turns out, the characteristics required for the separation 
and analysis of small molecules are different than those 
for proteins because proteins are much bigger. It is like 
comparing a marble and a beach ball.  The aspirin is the 
marble, and a protein, like some of the therapeutics used in 
chemotherapy, for instance, is about the size of a beach ball.  
Because of their different sizes and characteristics, proteins 
behave differently in separations, so we are really focusing on 
protein separations currently.  
Interviewer
So you essentially make instruments to separate proteins?
Elizabeth Cates
Yes. What we make is called a column. They are about the 
size of a pencil or a chopstick.  The column is a consumable 
piece that fits into an instrument. The instrument itself has 
pumps to pump solvents through the system, and then it has 
an injection needle to allow you to introduce a sample.
The column is where all the magic happens; it separates the 
components in the liquid into different compartments, if 
you will.  Imagine that you have a tube lined with Velcro 
and that you are going to throw tennis balls and golf balls 
through it.  The golf balls will not stick to the Velcro; they 
will just fly through and will all come out in one clump. The 
tennis balls, however, will stick to the Velcro a little; they will 
lag behind and come out in another clump. 
This is same principle behind chromatography. You get a 
time-based separation of materials with the column doing 
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the separation.  The columns are consumables, but they can 
be used multiple times.  Most columns have a lifetime of 
anywhere from three months to a year depending on how 
much they are used and what is being put through them. 
Interviewer
As a company, what challenges do you face or have you faced 
in the past?
Elizabeth Cates
As an entrepreneur in a startup company, I have had a very 
different experience than working in a large company.  Prior 
to this, I had worked in a medium- to large-sized company, so 
if I had a question about legal issues, like patents or business 
contracts, I would go to the legal department for help.  If 
I needed to buy something I would just fill out a purchase 
order and hand it over to someone else who would actually 
place the order.  If I needed a website, I would just talk to the 
IT department, and they would make the website.  
However, as an entrepreneur, you do it all yourself, so you 
have to be crafty about finding the right people with the 
right expertise when you need them.  Everything is, by 
necessity, outsourced, so you do as much as you can inside, 
but you have to understand the limits of your abilities and 
know where to go for help in the outside world. Fortunately, 
we have a lot of good resources available to us.
The Clemson University Research Foundation, CURF, has 
been supportive in terms of helping us find connections 
within the university and the entrepreneurial groups there. 
In Greenville, there is the NEXT organization, which is run 
through the Greenville Chamber of Commerce, and Brenda 
Laakso does a great job of organizing meetings for the 
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member companies. That group meets on a monthly basis 
for a round-table discussion of pertinent issues, such as how 
to find venture capital funding, how to do viral marketing 
for your product successfully, or what pitfalls companies 
frequently deal with. They are a great resource.  
The South Carolina Launch! organization has been a 
phenomenal resource for us as well, especially in terms 
of making connections and helping us find the resources 
that we need.  So there is a great deal of assistance for 
entrepreneurs to get things started, which helps make it 
easier.  I think for a lot of us, it is a rush trying to do it all; 
we just have to get our fingers in everything.
Interviewer
Do you have other people working with you?
Elizabeth Cates
I do. Right now, Invenca has three employees.  I am the 
chief technical officer and director of operations.  Mark 
Housley is our CEO.  He came from the same, medium- to 
large-size company that I had worked for previously, and his 
background is in new business development.  He did a lot of 
intraprenural work at this company, bringing in technologies 
and building businesses around them. He has seen and done 
it a lot and has built multimillion-dollar businesses around 
new technologies like ours.
He also has the finance, marketing, and sales background, 
while I have the technical and production background. 
Between the two of us, we cover all of the bases. Then I 
have a young lady working  in the lab as a technologist who 
actually handles most of the testing that we do.
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Interviewer
In terms of finances, how did you first get money to start 
Invenca?
Elizabeth Cates
Well, the first way everybody gets money is through friends, 
family, and fools, as they say.  Our initial fundraising was 
done through friends and family, and then it was extended 
to the existing investors in Innegrity, which is our parent 
corporation.  
Innegrity is the majority shareholder in Invenca.  They 
contributed mostly non-monetary goods, and after that, 
we received some funding from SC Launch.  I have been 
applying for state and federal grants and different research 
grants to help with some of the technical development work, 
and we are also currently raising funds right now for the next 
year to help get us through the product launch and to scale 
up.  
We are also looking to private investing groups like the 
Angel networks and some of the larger organized investment 
groups.  The American Chemical Society has expressed 
interest in investing in our technology, and we are talking 
to SC Launch! and other related groups about round-two 
funding.
Interviewer
Is it difficult to get that money?
Elizabeth Cates
It is. It is a scramble, but it really forces you to be creative. 
Two years or three years ago, it was so much easier to raise 
money; everyone had plenty of cash, and it was almost like 
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going to Vegas.  Everybody was willing to gamble a little bit 
on the slots, but that is not the case as much anymore. 
Now, you really have to have a good story to tell people.  I 
think we are in a really good position, though because we 
have a really great story to tell, and we have patent protected 
technology that is new and different.  It brings a lot of 
benefits to the market in this particular growth niche.
Interviewer
That is great. Now, where do you see yourself and the 
company in the future; what do you hope to do, or what are 
your grand ideas?
Elizabeth Cates
Grand ideas.  Every now and then, we come back from 
something, whether it is lunch or a meeting, and we go on 
about all of the things we would do if we had enough money. 
Overall, though, my grand ambition is to make an impact. 
Part of it is very personal because I am a cancer survivor. 
Advancing this technology will allow researchers to develop 
cancer therapeutics faster and get them to the market more 
quickly, which ultimately helps society as a whole and is a 
cause that is near and dear to me.
We want to be a good corporate steward, so we also approach 
our work from environmental and community standpoints 
as well. Community outreach is really important to us; we 
work with local schools and the community to help raise 
awareness about science and technology in our area and how 
it could really be a big boom for Upstate South Carolina. We 
really want to build a knowledge-based community, so that is 
another one of our goals right now.
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Our ambition is to grow as a company.  What you see in 
our industry is that the major players in the market address 
pretty much every market segment there is, but when it 
comes to developing new technologies, they keep their 
eyes out for what the small companies are doing. When 
something starts to gain traction in the market, they start 
looking for mergers or acquisitions.
Interviewer
Do you hope to do that or do you want to remain a separate 
company?
Elizabeth Cates
I think for me, the thrill is in the building of a business. 
Once the business is established and is in more of a 
maintenance and organic growth mode, I do not think it 
will be as exciting for me, and frankly, I do not think I am as 
good at running a business in that stage.  There are people 
with different skill sets that are better at that sort of thing.  
As such, I think I would be willing to hand it off one day, so 




Matt Gevaert is the co-founder and CEO of KIYATEC, LLC., 
which is based in Pendleton, SC. KIYATEC develops and 
commercializes enabling technologies for the pharmaceutical, 
biomedical, and life science industries.  The company focuses on 
advanced in vitro diagnostic capabilities for analyzing cell-material 
interactions and drug discovery.  KIYATEC lab-based technology 
provides more accurate simulation of phenomenon inherent within 
the living systems of the body.  Accurate modeling of these dynamic 
conditions provides opportunities for advanced medical treatments 
and enhanced diagnostics.  This interview was conducted in 
August 2007 at the Clemson University Renaissance Center. Since 
this interview occurred, the company has secured $175,000 in seed 
funding and has established operations in a wet laboratory and 
office space in the Center for Applied Technology (CAT) Incubator. 
KIYATEC’s focus is currently on product development and 
advancing applications for its 3-D cell culture technology platform. 
KIYATEC hired its first full time employee, a Cell Culture 
Scientist, in June of 2009 and was using its product internally 
in laboratory experiments in August of that year.  After securing 
additional seed funding in September and closing the seed round 
entirely, founders Gevaert and David Orr joined the company full 
time shortly thereafter.  The team will utilize the seed funding 
to pursue product development and its demonstration in large 





Tell me the story of how you started KIYATEC.
Matt Gevaert
I came to the United States from Canada to do my 
graduate work at the Clemson University Department of 
Bioengineering because of its reputation in bioengineering. 
I had an undergraduate degree in chemistry, and I wanted 
to get Master’s and Ph.D. degrees with a biomedical focus. 
There were only a few such places to go with a chemistry 
background in 1996 because most bioengineering programs 
focused on the engineering side of things, but not so much 
on the material side. However, Clemson has this 40 plus-year-
old program in biomaterials and professors who wrote most 
of the textbooks in the bioengineering field in the 1970s.  So 
to Clemson I came.  
While I was a graduate student, I went through the 
invention-disclosure process several times.  If all of these 
patents are eventually issued, I will be an inventor on four 
patents as a graduate student on three different topics, which 
is a little unusual.  
Some of the technology transfer staff have kindly called me 
prolific.  I think I was just annoying.  I was that guy who, 
when they said as part of the patent process, “We will do 
such and such within two months,” I would wait two months 
and a week and then go back and say “Okay, what is going 
on?”  So, I got to know everyone in the Clemson patent 
office (Clemson University Research Foundation).
I had invented some things that I thought were interesting 
and would have commercial value. The first invention was a 
co-polymer.  If you have ever had stitches that go away, they 
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are made of the molecule lactic acid.  Lactic acid is produced 
when you exercise; you get sore because of lactic-acid buildup. 
It is a natural product, and your body knows what to do with 
it.  When lots of these little lactic acid molecules are knit 
together, long chains form.  These long chains make up the 
plastic used to produce those stitches that “go away.”  This 
co-polymer could also have usefulness for incorporating 
drugs into absorbable materials.  A patent on this co-polymer 
has already been issued.   
The second invention, which was actually a  catalyst of this 
company, is a tool used in labs to grow cells in a certain way. 
A patent on this technology has also been issued.  
The third and fourth inventions relate to a very tough kind 
of plastic that might be used in an artificial hip, knee, or 
spine.  It was the focus of my Ph.D. work, which was done in 
collaboration with a company in Canada.  The quick story 
there is that with the blessing and support of my advisor 
(who also had some money, which is important) I looked up 
an old connection of hers, and said, “Hey, let’s do a project 
together. I do not want money.  I want you to teach me 
how you make these really tough plastics, so that we can 
deconstruct it and then put it back together in a way that is 
biocompatible for use in medical devices.”  So, that made up 
inventions three and four.  After graduation, I held a one-
year post-doctoral position at Clemson, working primarily 
with the Canadian company on the plastic compound.  
After that position, I worked at CURF (Clemson University 
Research Foundation) on technology transfer projects.  
But let’s bring our focus back to the inventions. Again, 
invention two is a tool for laboratory use.  I have a 
friend, David Orr, who was also a colleague in the Ph.D. 
ACORN 101
bioengineering program at Clemson and also had a 
laboratory tool.  
Around the summer of 2005, David and I had both invented 
small plastic pieces that could be used in a lab to grow cells.  
At the time, he had his MBA and was getting his PhD, while 
I already had my PhD and was beginning to gain interest in 
the commercial side of things. We were also good friends, so 
we decided to go into business together.  
We founded our company: KIYATEC.  You might wonder 
about the name.  It is based on a Hebrew word, but we 
mutilated it a little bit to make it an English word.  The 
Hebrew root word is “chayah,” with a C H.  If you have 
seen the famous movie “Fiddler on the Roof,” you might 
remember them saying “La Chiam,” which means “to life.” 
So, KIYATEC, after Anglicization, roughly means life 
technology, or technology centered around life.  
Interviewer
Tell me about how those ideas came about in the lab.  
Matt Gevaert 
I can answer this question for my invention better than I can 
for David’s.  My Master’s project was creating an absorbable 
polymer, and then my Ph.D. project was creating a non 
absorbable polymer. Both times, my committee said (and 
reasonably so) “Talk about how toxic the material is. You 
have to prove that you can put it inside someone’s body and 
it will not poison them.”  
The first time around with the absorbable polymer, I 
stumbled into this problem: I wanted to be able to look at 
how cells grow on this material.  What I wanted to do was 
102 KIYATEC
put the cells right on top of the material and see if they 
would stick.  If they did, I wanted to know how they grew 
and how fast they multiplied. These types of answers are 
important indicators of how toxic the material is going be. 
However, the existing ways to address this problem were, in 
my mind, not robust enough to give me the answers that I 
wanted.  
For example, a conventional method to test a material like 
mine is to grind it up, soak it in a medium, and then take 
that liquid and test your cells against it.  That will tell you 
whether it is going to leach out anything or not and whether 
the leachables are toxic.  This test is important, but not what 
I wanted.  There are some other ways people try to do this, 
but few of them were suitable for my material.  So, when 
I did my Master’s thesis, I did not include any tests in my 
results that were done exactly the way I wanted because I did 
not have the method to do so.  That was the catalyst of my 
idea.  One of my committee members was Dr. Karen Burg, 
and after switching projects from my Master’s to Ph.D., I 
said to her “I would like to revisit that problem.  I have some 
ideas on how we might go about solving that testing need in 
a better way.”  She said yes, and gave some other suggestions 
as well.  Between the two of us, we came up with a design.  
The device that we developed is essentially based on the 
design of a cell-culture “Petri dish.”   If you have watched 
the television show “CSI,” you will often see them looking at 
cultures in a six-well Petri dish-type configuration (or twelve-
well or twenty-four etc.).  Dr. Burg’s and my invention is an 
insert that fits on top of the Petri dish shape and holds the 
plastic (or other material) to be tested down, so you can grow 
cells on it.  There were a number of variations that we could 
have generated based on this design, but ultimately, we did 
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not go with it but instead went with this (a 3-D cell culture 
chamber).  
The device has ports on either side going in and out, so fluid 
can flow in two parallel paths.  There is a little chamber 
about the size of a pencil eraser.  There is one on the top and 
one on the bottom, and in between, there is a membrane.  
You can grow cells in three dimensions in that chamber.  
Instead of growing them in the Petri dish configuration, 
which is two-dimensional, you grow them stacked on top of 
each other in a 3-D configuration.   
Cells grown in three dimensions behave much more like 
those in your body since the cells in your body also grow 
in three dimensions.  When growing cells, you want to get 
relevant and useful information, and when the environment 
for growing these cells is more like it is in your body, then 
the results of those tests are more valuable.  
The 3-D cell culture device is based on David’s Ph.D. work. 
His invention was also co-invented with Dr. Burg, and it also 
went through the patent disclosure process. We both worked 
with Dr. Burg as students independently of one another. 
Their invention involved growing cells in a way that was 
more physiologically relevant.  In fact, his project started as 
a project actually working with stem cells.  Just to be clear as 
far as that goes, there is no controversy relevant to his work; 
there are many different kinds of stem cells, and we have 
always worked with adult stem cells only. 
For David’s Ph.D. project, by using the same stem cells on 
either side of this barrier, he grew cells that changed into 
bone on one side and cells that changed to cartilage on the 
other side.  The result was a little plug that was half bone 
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and half cartilage.   This would very valuable for people with 
cartilage defects, say as a result of a car accident or some 
kinds of arthritis.  Cartilage is very hard to work with; it is 
avascular and gelatinous, and it is not easy to get things to 
stick things to it.  This idea, then, has a lot of potential, but 
it was still very far away commercialization.  
But, back to the formation of KIYATEC. David had this 
invention, and I had one similar to it, and we said: “Okay, 
these are both technologies that we can commercialize 
synergistically inside this company.  In order to do this, we 
will need a lot of the same things:  injection molding and 
incubators to grow the cells and to conduct a number of 
tests on the materials and the process.  And, we will need to 
figure out a way to market and sell these devices.”  
So, this was the formation of our company.  It made a lot of 
sense to us, and we were both excited.  We both recognized 
the value of doing it together instead of apart, so we formed 
the company around these two technologies.
Interviewer
On what date did you incorporate your business?
Matt Gevaert
I believe September 1, 2005 was the legal day of 
incorporation.  The discussions started probably that spring 
and went into that summer. 
Interviewer




We did, but since we were cash strapped, there was a bit 
more to it than that.  We did some research on possibilities 
for finding money to help pay for business development 
expenses, and we identified a program called SBIR Phase 
Zero (SBIR—Small Business Innovation Research.)  This 
program provides small grants, I believe up to $4,000, 
to help entrepreneurs submit for an SBIR grant to a 
government agency.  As part of the SBIR Phase Zero grant, 
there is a list of reimbursable expenses that you can accrue., 
which includes legal fees. We applied for and received one; I 
think our SBIR Phase Zero grant was about $2,000.00.  
We asked many people we knew about lawyers who were 
willing to work with startups and who might have reasonable 
fees on the front end and were known to do good legal work. 
While it would have been possible to do the legal work of 
incorporating ourselves, we decided to hire a lawyer because 
we both recognized that legal issues were not our strength.  
The legal aspect of incorporating the business was something 
that we did not want to make an early mistake on and then 
dread finding later.  Our initial legal costs were less than 
$1,000.00, and the SBIR Phase Zero program supported 
those expenses.
Interviewer
It sounds like the first part of the process was that you had 
the idea to commercialize these two inventions and then you 
received an SBIR grant.
Matt Gevaert
No, unfortunately we did not receive an SBIR grant even 
though we applied for one.  The purpose of the Phase Zero 
grant is to encourage people to apply for an SBIR grant. 
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Interviewer
And then what happened?
Matt Gevaert
While I was working a full-time job and David was 
completing his Ph.D., we ended up submitting three different 
grant applications that fall, which is pretty good productivity 
for the first four months of a company.  These proposals 
were targeted to supporting either of the two inventions since 
we did not know which one might be of interest to possible 
funders.  None of these proposals ended up getting funded, 
but we were also able to develop our business concept further.
Interviewer
Were your proposals submitted to major agencies, such as the 
NIH— National Institutes of Health?  
Matt Gevaert
There are many departments under the NIH, and these 
two technologies would appeal to different sections.  We 
had a strategy: this one fits best here; this one fits best over 
there. We were competing against bigger organizations 
and universities for these grants, and as I mentioned, we 
did not get funded.  But, in parallel, we were exploring the 
commercial side of things.  It was around the next spring 
that we started talking to people about the different devices.
Interviewer
Can you elaborate about what “talking to people about the 
different devices” means?  Who did you talk to? 
Matt Gevaert
We tried to figure out how we would go about making and 
selling these devices.  First of all, there is always the issue 
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of finance.  We needed capital, so we needed people who 
understood that we could make money on these devices. 
Then, we needed a way to get the products to customers, 
such as through big distributors of lab apparatuses. 
Therefore, we needed to know how these companies did 
business and who our major competitors in this field were. 
What we realized after exploring this industry is that we are 
a “tools company.”  We are not making a drug or an implant; 
we are making tools for researchers. We found out very 
quickly that many of those markets are pretty small.
In both my CURF position and in my entrepreneurial 
position, I found that many individuals have clever ways of 
solving problems in the lab.  These lab solutions are good 
ideas, they work, and they are often patentable.  But, when 
it comes down to it, there are not enough scientific labs 
around the country, or even around the world, to justify 
spending a lot of money to commercialize a product to solve 
these problems.  On the very extreme, if you are a very 
specialized scientist and you work at one of only three labs in 
the world that can do such-and-such research, if you create a 
tool for that specific lab, you can see that the market size is 
potentially three labs total.  
Now, of course, it generally does not work that way, but if 
you are going to raise money, you need to have a market 
big enough for investors to have a chance of making a 
substantial return back on their investment.  This was the 
issue with the first device, the one that I had invented. While 
it was closer to commercialization and a simple patent on the 
device was closer to being issued, the market was not large 
enough to sustain a large outside investment. 
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We thought we could get this device into the marketplace 
and generate a revenue stream and then use these revenues 
to develop the other device further.  However, what we found 
is that there was not a lot of investor support because of the 
small market size.  If we had a lot of our own money, we 
might have gone ahead with that device because it could be 
promising right now.  
I recently received something in the mail from a Finnish 
company who has a device that is pretty similar to mine, and 
they are trying to get market penetration.   However, because 
we do not have that kind of capital, we need to talk to people 
who can invest.  
We could obtain money through government grants, which 
we have pursued and are still pursuing, and then, there is 
private money as well.  There are tradeoffs between the 
two. Government grants often take a long time to get, but 
the money you receive is non-diluting.  Government funds 
also enhance your credibility because if you get funded, a 
specialist has looked at your proposal and judged it worthy 
of funding. But, government grants take a while to get.  If 
you apply for the grant and get funded, you do not receive 
any money for another six to nine months, and in the 
business world, that is a long time.  On the other hand, 
there is private money, which you can generally raise more 
quickly, but an equity investment dilutes the ownership stake 
of earlier investors.  So, we were trying to strike a balance 
between both.  
In looking at the marketplace, we found a number of 
possible uses of the 3-D cell culture technology.  One 
application would be for drug discovery.  There are a number 
of different estimates, but it appears that between $800 
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million and $900 million is spent in production for each new 
drug that comes out.  There are a number of steps in drug 
discovery that occur before these drugs reach clinical trials.  I 
am oversimplifying the process, but conceptually, companies 
initially test new drugs with a very simple biochemical 
assay.  Then they might move to testing the drug on live 
cells, cultured in ways like the one we just discussed.  From 
there, if it passes muster and everything else works out, they 
would move towards testing the drug on animals to study 
the drug’s toxicity and effectiveness. After these studies, they 
would consider testing the drug on people.  By the time the 
drug is used on people, it has gone through a long process of 
testing. On average, for every 10,000 new drug compound 
candidates, only one makes it through.  It is a long and costly 
process. 
Our invention allows us to grow a certain cell type on top 
and another cell type on the bottom, which creates a 3-D 
test system.   Cells in this system behave more like cells in 
the human body when interacting these different drugs. 
Secondly the 3-D cell culture method, although it is not yet 
standardized, is used in some form in many labs already. Our 
product creates a way for multiple cell types to “talk” to each 
other while growing in three dimensions, which is hard to 
do using existing equipment.  
I will give you a good example that I am preparing a 
grant application for: Cancer.  For cancer studies, many 
researchers have said that previous 2-D cancer studies are not 
meaningful because you have to grow cancer cells in three 
dimensions to make them behave as they do in the body.  If 
you test an anti-cancer drug against cancer cells grown in 
a 2-D environment, you might not be getting an accurate 
answer of whether it will actually work or not. 
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Another strong point of interest is liver cells.  Drugs are 
processed in the liver, but when they are, the liver may 
potentially alter the drug; the liver might tweak it a little 
bit into another compound entirely.  It is important to 
understand how that occurs. Does the drug become more 
effective?  Does it become less effective?  Is it toxic?  
So, what I am proposing in this grant application is to be 
able to culture liver cells three-dimensionally on the top and 
cancer cells on the bottom.  Then, I would test this mini-
biological system using four drugs that are already known to 
be significantly affected by liver-cell processing.  
Two of these drugs are known to become more effective 
when they are processed by liver cells, and you can 
understand why this is important to know.  The other two, 
however, are known to become less effective when they are 
processed by liver cells.  If I can use this invention to test 
these drugs and tell exactly how they affect the cancer cells 
growing adjacent to them, post-metabolism by the liver, I 
would be able to provide drug companies with very valuable 
information. I will demonstrate this using four drugs that 
we already know affect the liver in particular ways.  By 
implication, if we can test four drugs with this invention, 
then we can test ten or 100 more drugs for which we 
currently do not have answers.  With this invention, I can get 
answers cheaper and faster without involving people.
This is the essence of the technology.  KIYATEC will 
eventually make instruments with a lid that can be opened 
in which ten to twelve of these little cubes can be plugged. 
These cubes have conditions in which you culture cells: at 
the right temperature, at the right humidity, and at the right 
carbon dioxide level. 
ACORN 111
We envision that drug companies will use this tool to 
determine how effective a drug is going to be. I just gave 
you one example of culturing liver cells with cancer cells.  
There are a lot of different possibilities: if you are trying to 
construct a drug for diabetes, you might want to culture 
pancreatic islet cells, or if you want to test a drug to see how 
much of it resides in fat cells, you could also do that.  
Interviewer
Tell me more about the commercialization process, in terms 
of discovering your market for this invention.  
Matt Gevaert
I have sought to develop relationships with people engaged 
in drug discovery, people who would understand the value of 
this invention.  They understand that we need better in vitro 
assays to do drug testing.   The drug people are saying, “Well, 
show us.  Prove that your invention can do what you say it 
does.”  So, this is the stage of commercialization at which we 
find ourselves: needing to raise money to do proof-of-concept 
studies for the drug application.  
We have already proven the effectiveness of our other 
application for the research market, but for this particular 
market (testing drugs), we want to be able to show that it 
works on known drugs first.  The next step would be to test 
it on more drugs: say, ten drugs for which drug companies 
already have answers, but we (KIYATEC) do not. Then, we 
will test the device on ten drugs for which even the drug 
companies do not have answers.  We have to demonstrate 
the value for a particular application for each customer.  
Risk goes down as time goes forward.  Right now we are in 
an area where they want to see the invention mature a little 
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bit more.  They want to see the invention’s effectiveness 
more readily for these particular applications, and that is the 
challenge.  I think my immediate focus is going back towards 
government grants because this is an interesting scientific 
problem, and it will be valuable if we can show that it works.  
A number of people have asked about whether they can 
invest in the company.  I want to hold off on that issue until 
I get some of the other questions answered.  I think that you 
have to build value into your company to a point where you 
can actually accept money.  It makes sense for downstream 
dilution issues.  Many of the venture capitalists I know have 
explained that it makes sense to prove the technology first 
before taking outside investment money. So that is what I am 
trying to do.
Interviewer
Did you do a business plan?
Matt Gevaert
Yes.  I will give the credit to David for this.  He was the 
mastermind behind most of the business plan writing.  
He graduated with his Ph.D. in the fall of 2006.  He was 
working full time with the company and dedicated his time 
to writing a business plan, among other things.  
We have an award-winning business plan.  We entered and 
won the Charlotte Five Ventures Business Plan competition 
this last spring.  We competed against teams mostly from 
North Carolina.  We made the top three among non- student 
teams, and then went to Charlotte for a day, where we met 
with review panels, had discussions, and engaged in mock 
scenarios of investors and companies asking us about the 
technology.  Again, I will give David credit.  He championed 
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that process, and we came out with the win. So, we have an 
award-winning business plan.
Interviewer
Did you find the business plan competition valuable?
Matt Gevaert
Yes.  It has given us a lot of good exposure.  Winning the 
competition adds some credibility to what we have done.  I am 
still realizing the value of that.  For example, we now know a 
lot of business people in Charlotte.  So, yes, absolutely.
Interviewer
Is there anything missing from the story?  
Matt Gevaert
What is missing from this story is that after we won the 
business plan competition, you should be asking yourself, 
why I am sitting here, and not David, who I have mentioned 
many times.  
Picture the scenario that David, as a young entrepreneur, is 
also married.  He finished his Ph.D. in August, so now he 
is with the company, but we do not have money to pay his 
salary.  This was a challenge of whether we could raise some 
money, and get this money into the company in time to 
actually start paying him a salary.  He has a Ph.D. and MBA.  
He has some very valuable skills, and at the end of the day, 
we were not able to raise the money to have him employed.  
So he has taken a job up in Indiana with “Cook,” a great 
medical-device company that has need of a similar set of 
skills. 
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As a result, we have shifted from where before I was in the 
passenger seat in terms of ownership and responsibility to 
where I am now in the driver’s seat in terms of both of those 
things.  So now, it is up to me to lead things forward as far 
as it can go, and this is what I am trying to do.  But sadly, I 
have to note that this region lost a great entrepreneur to a 
job up in the Mid-West.  
In retrospect, I think we were a ahead of the curve on a 
couple things.  If you look at the developing infrastructure in 
this area for entrepreneurial activity, young companies like 
KIYATEC are growing.  So, there are options available now 
that were not a year ago, which is definitely good.
I guess those things were not in place quickly enough for 
our company, and/or we did not click into what was in place 
soon enough to have made it work where David would still 
be here.  We certainly have had our struggles and learned 
lessons on the way too, and I am still looking for that grant 
or something else to get things going.  I might also talk to 
some investors in January.  But either way, our goal is to 
get some money into the company by next summer and to 
go forward with developing the invention concept and its 
validation and then to go from there.
Interviewer
I know some people are interested how technologies from 
Clemson University are licensed.  Since you have been 
on both sides of the licensing process as both an inventor 
at Clemson and as a licensor of this invention, could you 
explain how does the process work? 
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Matt Gevaert
Basically there is usually some upfront consideration, quid 
pro quo from the company for the use of the asset “as is”: 
early and often unproven but still representing something 
in which the university has invested resources.  Part of a 
standard license also involves royalties, which people tend 
to focus on, but royalties do not come into play until you 
actually start making sales, which is downstream.  Typically, 
there is an understanding that these technologies often take 
several years to commercialize.  For example, there are no 
royalty expectations on this technology any time in the next 
year.  If I did start making this invention and selling it, then, 
yes, there would be some royalty expectations.  
Interviewer
My sense is that there is a basic understanding that 
technology commercialization takes a long time, and the 
university is saying “let us put these patents out in the world 
and have companies commercialize them” and that there is 
a royalty if it works and sales are generated from the patents.  
But probably most of them do not work. However, some 
of them do, and these are the ones that provide revenue to 
Clemson.  
Matt Gevaert
Yes, that is exactly right.  There is an understanding that it 
takes time, and there is an understanding that most of the 
patents will not work or be valuable in the market.  The 
university’s job, with which the technology commercialization 
officers are involved, is to create the possibility that patents 
generated at Clemson University are licensed by others and 
commercialized. 
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The goal is to create a good licensing deal that makes sense 
for everybody.  The deal should make sense for the company 
who takes the technology in, and it should make sense for 
the university who passes it out.  For example, the university 
is concerned that companies will license technologies and 
not do anything with them.  So, there are typically provisions 
to ward against companies just licensing technologies and 
sitting on them.  Most licensing contracts have an annual 
minimum companies have to pay to maintain the license, 
or if the company has not sold the first product by a certain 
date, then the license expires. Provisions like these are 
certainly always in place as well.  In licensing a technology, 
we look to see whether the company is really trying, doing 
a good job of commercializing the technology, and moving 
things forward.  
But they are also structured in a way that makes sense for a 
young company that is not going to have royalties any time 
soon.  In addition, there are ways to offset the initial cost 
required by a company for the upfront licensing fee.  The 
research foundation, for example, may ask the company for 
equity in the business in lieu of a cash fee.  In this way, the 





In the following interview, Andrew Clark, Chuck Pringle, and 
Brent Buckner discuss the founding of SensorTech, LLC., a 
startup company that emerged from research done at Clemson 
University. SensorTech specializes in the development of a novel 
contact sensing material that can be used in a wide array of 
industrial applications. While doing research as a doctoral student 
at Clemson, Andrew discovered a method for conducting electricity 
through a polymer to create a sensing material.  This research and 
resulting technology became the foundation of SensorTech, which 
Andrew and Chuck founded in May 2007.  The initial technology 
was used to create trial tibial inserts for knee replacements and has 
expanded to include load cells and stent-testing devices.  SensorTech 
was originally based out of the Griffith Building in Pendleton as 
part of a Clemson incubator but has since moved to a new facility 
in Greenville.  At the time of the interview the company was 
working on negotiating contracts with the Applied Research and 
Development Institute and the Department of Defense to establish 







Please introduce yourselves, and then tell me the story of 
how you got into this business.
Chuck Pringle
I am Chuck Pringle, CEO (Chief Executive Officer) of 
SensorTech.  
Andrew Clark
I am Andrew Clark, CTO (Chief Technology Officer).
Brent Buckner
I am Brent Buckner, Director of Business Development and 
Administration.
Chuck Pringle
SensorTech was started as an outgrowth of Andrew’s work 
in the BioEngineering Department at Clemson.  Andrew 
went to Clemson for his entire educational career; he 
earned his Bachelor’s, Master’s, and PhD degrees here and 
graduated in May 2007. During the course of his graduate 
studies, Andrew started to work with UHMWPE, which is a 
high-strength polymer, and discovered a method to make it 
conductive so it could be used in a variety of measurement 
applications.  Initially, he did some work centered on load 
cells as they are used a great deal in industry.  He also began 
working on a “smart” trial tibial insert that is used in total 
knee replacement surgeries.  The patent is actually based on 
this body of work.  These inserts are becoming increasingly 
important because the number of such surgeries is rising 
steadily in our aging population.
In January, 2007, Andrew and I began discussing what he 
wanted to do with his PhD after graduation. During the 
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first half of 2007, we took advantage of an exclusive option 
to license technology from Clemson University through 
CURF (Clemson University Research Foundation).  We 
eventually began moving in the right direction to developing 
our company and establishing our initial business activities. 
Around the first part of July 2007, we obtained some space 
in the Griffith Building in Pendleton, which is a CURF 
facility for advanced materials and an incubator for startup 
companies.  We had to set up a lab space, which essentially 
took up the rest of the summer because we had to identify 
and procure the equipment required for our work.
The equipment started to arrive around the first of 
September, and soon after, we realized that we would have to 
leave the CURF facility due to lack of space.  As of January 
2008, we completed the move from the Griffith Building 
to our new facilities in Greenville.  Actually, we are having 
our lab floor finished today, and we will be moving into the 
space tomorrow. SensorTech truly is a startup just getting 
into business.  
Those were some of the first steps we took.  We received 
our initial funding from a $50,000 university startup grant 
from CURF and SC Launch, and we also received some 
money from friends and family. Our plan for the fall entailed 
further technical characterization of our materials. This type 
of characterization is a common technical task in the sale of 
products and goods, so we put a good bit of time into that.
However, the material characterization process was hampered 
a bit by our initial lack of space and by the few times we 
relocated within the Griffith Building.  So we had a few 
stops and starts in the Griffith facility, which motivated us 
finally to relocate here.  I have to say that Andrew did a very 
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good job during that time, especially because the work was 
very difficult and we did not have a fully functioning lab.
Andrew’s initial work was so intriguing that we even had 
some interest shown by outside companies during the study 
period. People wanted to talk with us directly about what we 
had, perhaps even before we were quite ready for them. We 
were also encouraged by the load cell market research we had 
done with Spiro International.  
At the same time, we had some initial conversations with 
ARDI, which is a technical institute joint venture of South 
Carolina Research Authority and Clemson University. ARDI 
is working on a R&D contract from the Office of Naval 
Research pursuing solutions for naval material issues.
Through this relationship, we also became aware of a 
program that they were working on in prosthetics. Long 
story short, we have submitted a proposal to them to develop 
a material for using in fitting prosthetics.   It should be a 
significant award, especially for a startup company. ARDI’s 
interest further solidified our initial thoughts that our 
material could be used in a wide array of applications and 
would have significant advantages over existing products in 
the marketplace.  
Overall, there are still some medical applications that hold 
promise, but we believe that our near-term success will be 
to begin on the ARDI contract and, at the same time, add 
additional resources in order to begin looking at load cells in 
earnest.  During the remainder of the year, those two things 
will probably be our focus areas, trial tibial inserts and 
stent-testing devices.  We are very encouraged.  That is pretty 
much where we are.
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Interviewer
I have a lot of questions.  First, can we start with some 
issues about the technology?  How did you decide on what 
particular ideas or commercial ideas you wanted pursue?  
Andrew Clark
Just common sense, I guess. We just saw where our 
technology might fit and what its potential was.  As a 
research engineer, when you work with something for so 
long, you intuitively know where your technology can go. 
Brent Buckner
Well, I think one of the challenges that we are having right 
now is that we need to concentrate on one major focal point 
that will become our revenue driver. We know we have these 
three focal areas (load cells, prosthetics, and smart trial tibial 
inserts) pretty much locked in, but we need to decide in 
which area we are going to create a functional product that 
will produce revenue over time so we can develop and market 
these other ideas.
We probably have 50 or so research and development ideas 
that seem to come up on a daily basis.  So our challenge right 
now finding something that will generate a steady stream 
of revenue for us, but we have to do a little more research 
before we reach that point.
Chuck Pringle
I want to add a little something to what Brent’s saying about 
the load cells and go back to what Andrew was saying as well. 
In the course of this work in the lab at Clemson, Andrew 
used load cells successfully in some of the testing that he was 
doing.  So, he became aware of their functionality early in 
his research.  
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Interviewer
Now, can you describe what a load cell is in layman’s terms?
Andrew Clark
Okay.  A load cell is a device that measures load, like 
mechanical forces.
Interviewer





Load cells are ubiquitous in industry.  They are used in many 
applications from load cells in your bathroom scale at home 
all the way up to load cells weighing tens of thousands of 
pounds for industrial purposes. Inside a load cell, there is a 
device called a strain gauge, which creates the measurement. 
The load cell is a device that surrounds the strain gauge and 
enables it to conduct the current into an external device 
that gives the output. Load cell technology has not changed 
much in 30 years so there is incredible opportunity for us as 
verified by our market research!
Interviewer
So a load cell is essentially a polymer with properties that 
produce currents when pressure is applied, and then you 
get a sense of how much pressure applied by measuring the 
current.  Thus, load cells can be used many applications. 
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Chuck Pringle
One of the beauties of being in the Upstate is that there is 
a lot going on here technology-wise that we can get involved 
with, from work at the Clemson University International 
Center for Automobile Research (CU-ICAR) to work of 
the Greenville Hospital system.  There are a number of 
companies that work specifically with vascular technology.
We are also doing some work with CU-ICAR. After Andrew 
finished up his initial graduate work, I would say that 
there was at least a modicum of interest in our work from 
mechanical engineering faculty.  Some of those faculty 
members have since relocated to the CU-ICAR campus, so 
we plan to continue interfacing with them in the future.  
Also, we have talked to Michelin and BMW about some 
automotive-related applications.  So those are examples of 
things we will get to at the right point in time, but we are not 
quite ready for that right now.  
In the short term, we will be doing more evaluations on the 
load cell.  I should make one other point.  The money that 
we received from SC Launch also came with some resources.  
Warren Weeks, who was the technical director at SC Launch 
when we received the money, came to us to discuss our 
product and its applications.  
Fortunately, we will not be asking for money from external 
investors for a while, which will save us some time and 
energy. We want to make sure that we have a much more 
solid story before we go to a group of external investors.
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Interviewer
Great.  So, can you tell some stories about how you got 
involved? 
Chuck Pringle
I have known Andrew through his parents before he was 
a student at Clemson, so I knew what he was up to at 
Clemson. As he approached graduation, I went to visit him 
to discuss setting up this business.  We decided we would 
make a good team because Andrew has the technology skills, 
and I have a long-term set of business skills and some extra 
time because I retired early from Fluor. That is how we got 
matched up, and then Brent came on during the fall.
Brent Buckner
I am a former banker and finance person. Before I took this 
job, I was working at a bank in Chicago and just got really 
burned out because I was on the investment banking side. I 
am originally from Greenville, so I moved back here and was 
really just searching for something different. 
I was looking at a couple of different opportunities, and 
then Chuck and introduced me to the company and the 
work they were doing.  I was looking for something that had 
a vision and ideas that I could get at the front end of and 
really explore with the new company, and that is what we 
have here.  Everyone is very passionate about what we are 
doing here, and that was something I definitely wanted in a 
new job. As soon as Chuck called, I came in, and we started 
working on an ARDI proposal.  It has just been a blast 
getting to do something enjoyable.
So starting up with a new company is exciting (and 
sometimes stressful), but in the end, the reward is going to 
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be great.  So, that is how I got on board with everybody.  I 
bring a different side that I think is unique for this company: 
we have a scientist, the guy with the idea; a veteran, Chuck 
who has been around business for a long time; and me, who 
brings the financial and sales skills.  As you can see, we are 
pretty well-rounded right now, and we are going to continue 
to grow in the future.  
Interviewer
What do you see as your biggest potential problems, and how 
are you surmounting them?  You might want to think about 
the history of the problems the firm has encountered.  
Chuck Pringle
Probably the biggest issue we have faced so far has been 
the whole space issue.  We really wanted to be part of the 
incubator at the Griffith Building.  
I would say that a lot of problems were avoided due to the 
initial funding from SC Launch.  When we started, the 
whole startup company incubator picture in South Carolina 
was in its infancy, and everyone (including us) was going 
through growing pains.  Since moving to our new facility, 
we have missed having the camaraderie of the other startups 
in the incubator.  However, we have planned to meet with a 
few of them, Selah and Tetramer specifically, on a periodic 
basis and share stories and business opportunities.  This 
is important because we hope to do some symbiotic types 
of work with both of these companies in the future, even 
though it will not be quite as easy as it would have been had 
we stayed in Griffith.
On the other hand, SC Launch has provided us with a set of 
resource partners to whom we gave a presentation earlier on 
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in our work. We will probably come back to them in the next 
few months to get some of their advice and guidance, but 
we will wait on that until we become a bit more mature and 
understand our own issues better. 
I would say the next issue we will face is the next level of 
funding.  We already have a fairly large contract that we 
are negotiating now, but we have to stop-gap finance that 
somehow, which is an issue that we will have to confront. 
SC Launch! may be a solution for that, though.  In addition, 
in our contract, we also have people who are willing to pay 
money for our product, so we have to evaluate some issues 
related to that as well. We will eventually go forward with 
external advisors and get some advice on how much money 
we are really going to need. 
I would say that if there was an error in judgment so far, it 
was that we discounted the startup costs.  We had different 
kinds of startup costs than the usual company, though; 
the whole lab and equipment is maybe a bit unusual.  We 
decided not to use lab equipment from Clemson. We might 
have been able to do that but decided that it would have 
been inefficient because we would have had to work around 
other people’s schedules.  So we bit the bullet and spent some 
money to obtain our own equipment.  
Also, let it be said that we did not do everything we wanted 
to do.  Andrew did a great job in keeping down the price of 
equipment. We have fairly nice equipment that we are proud 
to show anybody, but it is not top of the line.  I would say 
that Andrew’s got promise if he ever needs to pursue a career 
in procurement because he did a heck of a job with the 
pricing from our equipment vendors.  So, hats off to Andrew 
for being able to get that equipment for us.
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In Andrew, I think we have a technology guy who 
understands his product remarkably well. On top of that, he 
is not only a research guy but is also a very practical person 
in many ways.  He really put all this together. As a company, 
we are very lucky to have him because he is very handy. As 
he likes to say, he likes to find technology solutions to real-
world problems. 
Those are some of the issues that we are dealing with and 
how we are dealing with them, at least from my perspective. 
Anything to add?  
Brent Buckner
We have the same issues that I guess most startup companies 
have: deciding what equipment to buy; choosing what kinds 
of computers we need; finding a location for our office; 
finding funding; hiring new employees etc.  These are the 
types of things that any company would probably have 
to deal with, and we certainly have them.  These issues 
challenge us on a day-to-day basis, but that is what you have 
to do to run a company.  
Interviewer





We are, and it is very exciting.  It truly is.  I mean, one of the 
things that turned me on to this work goes back to when I 
was working with the South Carolina Research Authority 
(SCRA) where I was a board member and chairman.  As 
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I was exiting the chairman’s role, we were beginning to 
plant the seeds for what is now SC Launch!, so I was always 
interested in the subject of what goes on with research and 
how a company moves on to the “real world.” 
Starting this company was really a blending of my business 
and program and project management skills and Andrew’s 
technical skills. This blending resulted in the ARDI 
contract, which is a significant piece of research for Clemson 
University and for the upstate in general.
I was excited about the prospects for SC Launch!, and being 
where I was in my station in life, it was a no-brainer to work 
with someone who was passionate about what he had found 
and about bringing it to life.  Also, there were some real-
world applications that we had already seen relating to what 
he was working with, so I knew that this work was not going 
to be research just for research’s sake; this is an application 
that we are continually discussing and moving forward with.
Andrew Clark
I think that growing in Greenville is also very uplifting, 
especially after having gone to Clemson.  It is great to see 
how much excitement and work is going into companies in 
the Upstate and in South Carolina in general. There are a lot 
of good things going on here that make what we are doing 
even more exciting because we know that we have people 
behind us that want to see industries come into this state 
and make a difference.  I think a lot of good things are going 
to happen in years to come, especially in Greenville.
Chuck Pringle
In a year or two, we would really like to be a poster child for 
startups in Sough Carolina.  That is another of our goals.
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Interviewer
It sounds like you are really close.  One more investment 
here, one more project, and you have it.  
Chuck Pringle
Yeah, well, this is a significant project for us, and we are just 






John Ballato and Steve Foulger are two of the four founding 
members of Tetramer, LLC., and Earl Wagener is the company’s 
CEO.  In this interview, the three men tell about the founding of 
this faculty-based startup company and the unique challenges they 
faced along the way.  Tetramer was established in 2001 when four 
Clemson faculty members from different engineering and technical 
backgrounds decided to combine their knowledge and research 
interests to develop specialty polymeric and oligomeric materials. 
The company’s current research and development is focused on 
polymer fuel cell and gas separation membranes, biorenewable 
resources, piezopolymers, and optical polymers.  Tetramer’s research 
endeavors and unique products have enabled them to make 
strategic partnerships with larger industrial companies, including 
General Motors (working on fuel cell technology) and Cargill 
(creating renewable biomaterials).  Since this interview in,Tetramer 
has also created strategic partnerships with Membrane Technology 








Tell me the story of how you got into business.
John Ballato
I love telling this story. There are now three of us professors 
here at Clemson University all working in different 
departments: me, Steven Foulger, and Dennis Smith.  I have 
been here ten years, and I was hired into what was then the 
Ceramic Engineering Department.  
The next year, Dennis Smith was hired into the Chemistry 
Department, and the year after that, Steve Foulger was hired 
into what was then the Textiles Department. Through a 
series of interesting circumstances, we realized that we had 
a lot of complementary things in common in terms of our 
research interests.  
We had a chemist, an optics person, and a physicist. 
Originally, we had another partner, but he is no longer here. 
So, initially, we were just these four junior faculty from four 
different departments who really did not realize that it was 
not a typical thing in universities for people in different 
departments to talk to one another.  At the time, we thought 
that was common practice.  We realized later on that it was 
not, but we still began to share resources, laboratory space, 
and equipment.  
To make a long story short, these four people from essentially 
different walks of academic life came together because we 
were much more effective in doing the research we needed 
to do together.  As we began working together, we had no 
upfront thoughts about creating a company; we were just 
junior faculty trying to get promoted and tenured and were 
doing what we thought we were supposed to be doing.  First 
ACORN 139
we wound up founding a research center, COMSET, which 
has been very productive, and then we established Tetramer 
not long after that.
So, we did our research, published our papers, and went 
to conferences to present our work. As that work became 
better known, we were invited to speak at more and 
more conferences. After a few years of speaking at these 
conferences, people from various companies started coming 
up to us after our talks and asking us where they could get 
some of our material. 
Being junior faculty, we did not know any better and ended 
up just giving these people samples of our material to test. 
We did not realize that we were essentially testing markets 
that really did not exist at that point. Shortly after that, 
Dennis suggested that we start a company because there was 
so much commercial interest in our materials.
I think that is how many companies like ours start. We did 
not go in necessarily thinking about spinning out a company; 
we simply knew we had something of value, and there 
ended up being a market pull for the materials that we were 
developing at Clemson. 
Earl Wagener 
I think one of the pieces to the formation of Tetramer is that 
Dennis, who was at Dow Chemical for about eight years, had 
industrial background.  So, one of his natural thoughts was, 
“Hey, we can make this stuff and sell it.”
John Ballato
We began thinking about this idea of spinning out a 
company, and the first thing we did was contact Caron St. 
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John at the Spiro Center.  She gave us marvelous advice as 
far as what to do, what not to do, whom else to talk to, and 
what steps we should take, especially as faculty members.  
When we were beginning to set up the company, there had 
been maybe one case in which a faculty member had actually 
created a company, and there were some other horror stories.  
There are a lot more guidelines in place now to protect 
faculty and other people internal to the university when they 
want to take their ideas outside.
In many ways we were charting unknown waters, but this 
was something we wanted to do because there was interest in 
our materials and because we liked working together. 
After speaking with Caron, we found a lawyer and created 
the LLC (Limited Liability Corporation), Tetramer. 
Somewhere, I have all of these bar napkins on which we 
diddled out different names, and then we searched them on 
the Internet to see if they were taken. The etymology of that 
word came from “tetra,” which means “four” (because there 
was four of us), and “mer,” which is the root of the word of 
“polymer” (because we work with polymers).
Anyway, Tetramer was born out of this market pull for the 
materials that we had developed and are still developing at 
Clemson. Their performance was superior to many things 
that were on the market at the time.
The most important thing to the success of the company 
to date has been Earl Wagener. In our case, we liked being 
faculty members; we were good at being faculty members, but 
we are not good at running companies because we do not 
know anything about it.  Well, Earl does.
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Steve and Dennis have industrial experience, but working in 
a research lab for a massive company is very different than 
being the CEO of a small startup company.  So, the best 
thing we ever did was to get things started and then get out 
and give the reins over to somebody who actually knew how 
to run a business.
Interviewer
You said you never really got out, though, right?
John Ballato
Right. We are still involved; we just handed off that part of 
the business to people who actually know how to manage 
a company. That is another pitfall that a lot of faculty fall 
into: they see dollar signs in the possibilities of spinning 
off companies not realizing that very infrequently do those 
dollar signs ever materialize or at least not to the magnitude 
that they think they will.  
Many faculty members and most people in general, have 
egos that make them think that the work they are doing is 
the best out there and that people are going to give millions 
of dollars for their products. However, they have no idea 
about the other dynamics involved that make a product 
or an idea valuable or not.  So, they have these grandiose 
ideas of spinning out companies, making their fortune, and 
retiring on a lake somewhere, but it never happens. Very few 
people that get into academia actually make the transition to 
running companies. As a result, our decision early on was to 
find someone to run the company because we knew that we 
could not do it.
Low and behold, we found Earl Wagener, who is the perfect 
Clemson man for the job. Earl was born and raised in 
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Clemson, and his grandfather was in the first graduating 
class at Clemson and one of the founders of Clemson’s 
Chemistry Department. Earl earned his PhD here as well 
and just loves South Carolina in general.  He definitely 
bleeds orange and wears it. 
Earl Wagener
The situation was exactly that.  I earned my degree here and 
really wanted to stay in the Southeast.  Initially, I got a job at 
Milliken.  I thought I had nailed it right on because I looked 
really hard:  I looked in Atlanta; I looked in Columbia; I 
looked in Knoxville; I looked all around.  
I got the job with Milliken in Spartanburg, but two weeks 
later, they fired me because they had such a massive layoff 
that they just said they could not use me.  So, plan B was to 
go to Dow Chemical up in Midland, Michigan. 
I viewed the Midwest as this vast, cold, white tundra, but it 
was my only choice, so I left the Southeast, went to Midland, 
and worked at Dow. As it turned out, I loved Midland.  My 
philosophy is that you can enjoy anywhere you go if you take 
the attitude that it will be a great place.
I worked in Midland at Dow’s central research area and 
learned some background about the fundamentals of 
polymer chemistry.  Then, Dow offered me a job to set up a 
lab in Walnut Creek, California, which is near San Francisco 
and the Bay Area.
When I left Michigan, everyone kept telling me that my 
career would tank because I was leaving the center of Dow 
Chemical.  I just looked at them and said that it would not 
be bad out there and that I could help the company grow.
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The Walnut Creek lab was called Discovery Research, 
and we were looking at new things like artificial kidneys, 
membranes for gas separations, new polycarbonate-type 
structures, and that sort of thing. We also wanted to 
establish a lab in Japan, so I spent a fair amount of time in 
Tokyo, and we eventually set up a lab in Gotemba as well. 
That was a neat experience because I got to learn about a 
different culture and how research was done in Japan.
I was in Walnut Creek for ten years, and then I got an 
offer to go to Europe.  My family and I lived in the middle 
of Europe, outside of Strasburg or Baden-Baden.  The 
idea was for me to help Dow take the entrepreneurship 
side of the company into Europe and do new things.  So, 
I was out looking at acquiring companies and different 
technologies.  Then I was told that it was time for me to get 
back into the mainstream of Dow. So, I was sent to Texas 
and headed up the group called thermosets, which worked 
with polyurethanes and plastic.  I had a pretty high-level job 
at Dow while I was in Texas, but my wife developed a mold 
allergy while we were there, and I told Dow that I had to 
leave because my family life was in trouble.
I look at my career as having three foundations: my work life, 
my personal life, and my spiritual life.  A lot of people think 
that entrepreneurs have to burn both ends of the candle all 
the time, but if you do that, you will be a workaholic, and 
you will burn out.   And if you burn out, then you will not 
have the sensitivity to motivate and enjoy people or help 
them get through the tough times.
So, we moved to Chicago, Illinois where there were not many 
mold spores in the winters, and I was back in the Midwest 
shoveling snow again.  I worked for ten years as the Vice 
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President of Research and Development for a company called 
Stepan, which is a specialty chemical company. They wanted 
me to set up their European operation, so I was doing 
that when Dennis called me up and said “Hey, we have a 
company down here…”
Also, there is one thing that I forgot to mention about Dow. 
While I was there, I was asked to be part of what is called the 
Dow Capital Investment Finance Group.  I was the research 
component of this group that went out and invested Dow’s 
money into other companies.  The stipulation for these 
companies was that they had to have some way of tying that 
money back into Dow in order to create a synergy with Dow 
that would make them more money.
During this time, I got to see how a lot of small companies 
operated.  I saw just how tough it is, but I also enjoyed seeing 
how much they liked what they were doing. They barely had 
ten cents to make it to the next day, but they had the attitude 
that it would work. I always wondered, “Could I ever do 
that?”  I could not have managed it during most of my career 
because I had a family to raise, but then this opportunity 
arose, and here I am.
John Ballato
It gets better.  So at that point, I did not know Earl, but 
Dennis got his PhD in chemistry at the University of Florida, 
and his advisor was Earl’s brother.  Well, Earl’s brother 
actually got Dennis a job at Dow through Earl.  So when 
Earl decided to retire and move back to Clemson about seven 
years later, Dennis decided to return the favor by asking Earl 
to meet with us two days after he had officially retired.
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The company was about a year old at that point, and 
we ended up getting everyone together at a coffee shop 
downtown where Loose Change is now.  We just told him 
about our company and what type of work we were doing, 
and the rest was history really.
Earl Wagener
While we were having coffee, we talked about a lot of the 
projects they were doing, but the thing I looked for was the 
dynamic between these guys.  They could speak the truth as 
they saw it with each other.  If they thought something was 
right or not right, they would say it, but in the end, they liked 
each other.  That is what you need.  
You cannot have a small company and have one person with 
the attitude that he is going to take over the company at the 
expense of the other partners. That was not the case with 
these guys.  It still is not the case, even though it is becoming 
more difficult for them to spend time with the company with 
their growing careers in academia and everything else.  
Anyway, we looked at the products and asked ourselves what 
had been done before and what we could do. My natural 
instinct kicked in, and I told them what the critical values of 
their products were had how we would evaluate the product 
in industry. We sorted through each product and decided 
which to keep and which to let go of. 
We wound up with basically four platforms that were really 
interesting. When you are a small company (we only have 
eleven people now), it is tough because you get fewer at-bats. 
So you want to avoid going for the home runs at first and 
stay with the smaller stuff.
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Essentially, from  a career standpoint, you have to get 
back to zero, and it is good for you; it is renewing at many 
levels. Small companies usually last two-and-a-half years, 
but we are now on our sixth year and still going strong, 
and our revenues are increasing.  In fact, we just received a 
notification today that we are receiving another half million 
to continue our work.  
We deal with big companies like General Motors, for 
example.  General Motors is making a fuel cell car, and we 
are in line to make the fuel cell membrane for that particular 
car.  
John Ballato
You also have to realize that there is going to be some risk in 
things that are new.  In many ways, we got into things that 
really had nothing to do with our expertise. We have our 
material and know about that, but there are other aspects of 
the business (like using Linux, for example) that we do not 
know anything about.  We believe that our material is going 
to work.
Earl Wagener
In addition to working with General Motors, we still 
have the optical side of our work. We coat fibers for high 
temperatures and that sort of stuff, and we are looking 
into other optical materials as well.  For example, Sony is 
interested using our polymers as part of their DVDs. 
We are also looking at piezoelectricity, which involves 
taking a material and stressing or bending it until electricity 
is created by the tension. Or, you can put electricity in 
the material, and it will bounce up and down; that is the 
technology behind speakers, for example.
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We have found a way to make piezoelectricity six times more 
effective using our polymers than anything that is out there 
now.  The fact that we all have backgrounds in different areas 
helps tremendously because we can go to each other and say, 
“Does this really make any sense?  Is this worthwhile?” And, 
we can tell each other exactly what is going on.  
Then, there is the renewable area, which is going to be big. 
We are looking at taking renewable materials and putting 
them into industrial chemicals, like shampoos and plastics 
for example.  We want to find a way to convert soybean oil 
and vegetable oil and are actually working with a company 
called Cargill, which is the largest private food company in 
the world. 
Now, the neat thing about all this is that we have created 
twenty-five jobs.  We have eight PhD-level jobs in South 
Carolina, and we are going to keep on creating jobs. While 
eleven jobs is not a lot, if we get the sales we have projected 
and the grants we have applied for, we are going to have five 
more jobs next year.
John Ballato
As faculty, we initially started our work with research grants 
from the National Science Foundation and the Department 
of Defense. We only had a little “bubbler” in the lab and 
were just making small, amounts of our materials, just 
enough to take some measurements, write these papers, and 
go talk about our work.
Fortunately, for us at least, the devices that generally use the 
material only require a small amount. We had a material 
that was very high value but very low volume.  So, we did not 
need tanker cars worth of material, which was part of what 
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helped us get started.  We did not have to go into developing 
a commodity-scale material.  We could get away with 
something that was just very high value
So, Dennis, being a chemist, knew a gentleman who started 
a company at the University of Texas at Austin that made 
planar waveguide devices.  Planar waveguides are to light 
what integrated circuits are to electricity; they route the 
optical information around to be processed.
The plastic that we developed was superior to what was 
available for the types of things that they needed to do. After 
doing the math, we realized that we were capable of making 
the materials they needed because it would be done on 
such an elementary scale; all they needed was a thin layer of 
plastic that they could carve up, and we could handle that.
This was all around 2000 or so when the telecom bubble was 
just getting bigger and bigger. We were very excited because 
this company that we were making materials for was going 
to talk to Intel, which was essentially ready to make an 
investment.  That meeting was schedule for September 12, 
2001.
We all know what happened the day before, and that was 
the end of everything: no more investments; markets fell; 
telecom’s bubble burst. That was the end of that, and we 
were just sitting there thinking “Well, good thing we have 
faculty positions to fall back on.”
About a year later, there was another company in New Jersey 
called Lightspan that was doing similar work and producing 
planar waveguides as well.  We were very excited because we 
thought that our material was really going to revolutionize 
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the field.  But then, the head of that company, David 
Stone, died suddenly from a brain aneurism.  There went 
the company.  Again, we were thankful to have our faculty 
positions to fall back on. Really though, had either of those 
opportunities worked out, we would have been in trouble 
because we would have done okay for maybe a year, but we 
could never have scaled up beyond that.  We would not have 
known how to do it, and we would not have had the capital 
to do it either.
We probably would not be around if those first couple of 
things had come in.  We needed to start small, so we just 
kind of began bootstrapping these other things little by little.
Interviewer
Which means you were getting money?
John Ballato
Yes, we received money early on through small sales, testing 
the market, and small research grants.
Interviewer
Well, if people were really curious about your work, would 
they give you money?
John Ballato
Yes. Actually, the day we went down to the lawyer to set up 
the company and sign off on all of the paperwork, we had a 
$20,000 check from a company interested in our materials.
At first, researchers just wanted to test our material to see 
if it would work for their specific applications.  They would 
work for their specific applications.  They would say that 
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they just wanted a kilogram of our material to make some 
prototype device to see if it was what they needed.
So, we used the $20,000 check that one such company gave 
us to start up our own company and to purchase some scale-
up equipment and other supplies.  Then we took advantage 
of SBIRs, or Small Business Innovation Research grants. 
Now, there are a series of other grants, contracts, and monies 
that are coming in.
Earl Wagener
In terms of research, South Carolina needs to do a lot 
better. These SBIRs are basically the U.S. Council of 
Competitiveness’ way of making sure that innovation keeps 
going in the United States.  
These awards are $100,000, but the chance of being awarded 
one is only 8 percent.  Almost every time there is a call out, 
which is twice a year, there are 3600 proposals submitted, 
but only about 200 are awarded.  Eight percent is not too 
great; however, we have been awarded 13 SBIRs out of the 
16 we have applied for because Clemson’s technology is 
excellent.  
We have a tremendous business engine inside this university, 
but it really is not being tapped.  We can do a tremendous 
amount with it, and there is just more and more research 
that can be done.  
We already have a fairly decent reputation inside NSF 
because of our track record. Researchers from all over the 
United States apply for these awards.  We are competing 
against California, Michigan, Massachusetts, etc., all of the 
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big engines for innovation, and we hold our own with them 
very well.  
In addition, we work with many companies and have signed 
joint development agreements with them in return for 
funding, for example, our arrangement with General Motors 
for fuel cells.  In return, we have joint patents, which protect 
our ideas and allow them to have exclusive use of the patents 
in the automotive area.  
Fuel cells will also be used outside of the automotive 
industry. They are used in houses, fork lift trucks, laptops, 
and that kind of stuff.  We have the right to take the 
technology that has been jointly developed between our 
company and GM and sell it in the non-automotive area. 
We would then have to pay the other companies, like GM, 
a royalty for the joint patent, but we have the right to go 
explore that.  
So, as a small company, you need a partner.  You cannot do 
it all yourself.  You have to go out and sign joint development 
agreements and that sort of stuff.  
Interviewer
When did the business start to push in terms of product?  
It seems to me that people wanted your product before you 
were necessarily ready to give it to them.
John Ballato
Sometimes, it is just a combination of both a pull from 
companies and a push on our end. We got started because 
there was a pull from companies wanting our product.  The 
push began, essentially, to move into things like the fuel cells 
and these gas separation membranes.  
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We had a material platform that we knew worked for this 
one application.  That is why there was an initial attraction 
and people were pulling it out of us, but we knew that we 
could do more with the material than what we initially used 
it for.
So, we began working with the material that we had 
developed for one application and looking at it for other 
things, and then we began trying to push that towards GM 
and other companies.  
Earl Wagener
For example, Nafion membranes from Dupont are the 
standard materials used in the chloralkali and fuel cell 
industries, and the companies that produce these materials 
are huge, global manufacturers.   
We sent some competing materials up to GM and told them 
to test them to see if they worked as well or better compared 
to these other materials. We did a few tests on it ourselves 
and gave them our data, and they said “Well, if we can reuse 
that data, we might be interested.”  
The material actually worked quite well, but all GM could 
say was “How in the heck does a tiny company, in South 
Carolina of all places, outdo Dupont?”  And I said, “Good 
question.  Come on down and find out.” 
There is research proving that companies that startup at 
universities last a lot longer than their counterparts who go 
it alone. Here is the arrangement that creates a win/win: 
because I am licensing technology from Clemson, I have 
access to their analytical resources and equipment—for a fee 
of course. 
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We brought GM down and showed them that we have the 
technology and capabilities through Clemson to compete 
with larger companies. We took them through AMRL and 
showed them how we were doing the polymer fundamentals 
and understanding the kinetics of the polymer, how we put 
the polymer together, what a block copolymer looks like, how 
we actually sulfonate it, what type of yields we were getting, 
and so on.  They were impressed by our work and decided to 
bring down the next level of people, and I knew that once we 
got to the people in Detroit, we were in.
John Ballato
So, how does a company like Tetramer compete with 
Dupont? Well, we showed them that the Clemson facilities 
and that we have equipment that is as good, if not better 
than, what Dupont has, especially in the areas in which we 
work.
Earl Wagener
The resources these Clemson faculty need to do their work 
are expensive, but they can get this expensive equipment 
because they are good.  They submit good proposals, so the 
synergy begins to work.  Clemson makes Tetramer look good 
by providing resources, and Tetramer makes Clemson look 
good with its talent and success. A lot of that talent comes 
straight from Clemson; over the years, we have had about 19 
people work for us, and about 90 percent of them came from 
Clemson.
John Ballato
That is the loop coming full circle. When Earl graduated, he 
could not find a job in South Carolina.  Now, a lot of our 




It is by no means easy.  We are always looking for more 
money. Right now, we have SBIR money, but about 40 
percent of our other income is starting to come from other 
places. Some of it comes from General Motors, and Cargill 
is purchasing a lot of materials directly from us to help them 
work with some Nobel-Prize-winning technology out of 
Caltech.
John Ballato
For small companies, especially, you can never really be sure 
where the money will come from. I mean, you have so much 
money in the bank, and you have payroll.  One month, 
you may be fine, but the next month you may have to start 
worrying about bringing in more revenue.
Interviewer
So what was the most difficult challenge you faced as a 
company? 
Earl Wagener
I think one of the hardest things we had to deal with was 
product liability insurance.  The first time I sold some of our 
material, the buyers asked about this insurance because all 
big chemical companies have it.  I figured I better find out 
about that.
I called several different insurers that the bigger chemical 
companies use, and they basically said, “Let me get this 
straight.  You are a three-person company, and you want to 
sell chemicals right after 9-11.  These are chemicals, right?” 
I tried to explain that they were plastics, but chemicals are 
chemicals to these people.  They asked us questions like 
“Does your stuff burn?” or “Will it explode?” Of course the 
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answer to these questions is yes; they will burn and, under 
the right conditions, they will explode.
Well, they basically said that they could not risk insuring us 
because we might be a little terrorist group setting up a bomb 
operation.  It took me 18 months to find a small company 
out in Seattle that would actually sell us insurance, and 
it was from a guy that I knew from Dow who had broken 
off and sold insurance.  We had to get two million dollars 
worth of insurance, and it cost us an arm and a leg.  It cost 
us $8,000, and we had not even sold anything yet. But, we 
had to get it; whether we were going to sell 10 grams or 100 
grams, we had to have product liability insurance.  
The second challenge we have faced was finding quality 
health insurance.  It is ridiculously expensive.  We went to 
the Small Business Administration and said, “Okay, SBA, 
you have a pool of small companies.  We want to join that 
pool so we can get lower rates for insurance.”  No way.  It 
does not work that way.  Even if you are in a big pool, it cost 
much more for a small company to get health insurance than 
it does for a bigger company.
So, each one of our employees goes through Blue Cross Blue 
Shield, and it costs us $800 a month, but the insurance is 
really not that great.  We would like to be able to get into the 
state employment system as part of a start-up in an incubator, 
but that has not happened yet.
Interviewer
You talked about an exit strategy in terms of exiting everyday 
management.  Did you have an exit strategy before you 
started the business? 
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John Ballato
We did not have a strategy up front per se.  I mean, the 
strategy was simply that we knew we had to find somebody 
who actually knew how to run a business, and it was not us.  
So, the strategy was the realization that we could start up this 
company.  We could be technical directors, but we do the 
best work when we are in labs at Clemson innovating and 
working with our students. If we did not have this company, 
we could help drive technology, but having an exit strategy 
in that sense was the realization that we are not business 
people.  We had to find someone who was.
Interviewer
So, are you still the principals of the business?
John Ballato
Yes, that is right. So, the four of us all have equal shares 
in the company, 25 percent shares. So, yes, we are the 
principals, and we own 100 percent of the company.
Interviewer
That is why I was curious because the next question I want 
to ask is why did you even start a business?  Why not just 
license out your materials?
John Ballato
License to whom?  There was not anybody else. The polymer 
technology was essentially one that Dennis brought with him 
by and large from Dow Chemical.  
You can actually get into the polymer itself with Dow; 
however, for a company the size of Dow Chemical, this 
size business is of no interest to them because it is too 
ACORN 157
low volume and too low revenue. For a startup company, 
however, it is a great opportunity.
We were innovating on an existent polymer; it just was not 
sufficiently big enough to attract Dow, but there was this 
market pull.  So, we spun out the company to fill the gap 
that existed.
Earl Wagener
Part of the issue is when you have a product that you have 
to develop.  It has to have an application because most 
companies are not going to buy an idea that does not have 
a patent, and many times an idea takes three years to get a 
patent for.
So, if you license your idea, it does not have a lot of value 
even though people like to think it does. A technology 
transfer group will do what you are talking about; they 
will just license it, and the average licensing is low, around 
$2,000 or $4,000.  There are a few homerun ideas that can 
succeed going this route, but they are very rare.  You really 
have to develop mores applications before an idea has value.  
If you look at product development as a five-stage process 
with stage five being commercializing, you do not know the 
value of the product until you are in stage two or three. You 
may have a great idea that you are able to patent, but you 
do not know if your product is valuable until these stages 
because you do not have a customer yet. Your product is not 
worth anything until your customer tests it and says, “I got 
the same answer you did.” 
This is what happened with us when we worked with GM. 
If they had gotten one bad number, we would have been out 
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of the loop, even if their technician hooked up the machine 
wrong or the test was run incorrectly.  To them, we are just a 
tiny little company with another membrane.  
Interviewer
Did you ever think where you wanted to go in the future? 
Did you ever think that if you reached a stage with a certain 
number of products or product sales that you might want 
to ramp up, build a plant, and produce your products on a 




So, where do you see the company: as one that is going to 
license to larger companies to make these kinds of polymers, 
or do you see yourself in that business?
Earl Wagener
All of the above.  Okay, the materials that are PFCB oriented 
are high in value but small in volume, so we will definitely 
ramp up and make those. Basically, we can take care of 
making what we need with a 50-gallon reactor, and since we 
are selling it for $10,000 a kilo, we are going to make a lot of 
money.  We are in great shape in that area.  
In the renewable area with Cargill, we are more on the 
intellectual-property side because they want about 10-20 
million pounds of our material. We will make the first half 
million or million pounds, and at that point in time, we will 
ask Cargill if they want to take the product internationally 
and start to manufacture it because they have a lot of 
catalysts they can do that with.  
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Or, we will ask ourselves if we want to stay locally. South 
Carolina obviously went out of the textile business a long 
time ago, but the residual specialty chemical companies 
that made the dyes and chemicals to treat the fibers are still 
around. In fact, there is one such company over in Easley 
called Ortec that we have talked to, and they would love to 
scale up to the 10- to 20-million-pound range.  
We could carry it up through that level because at 20 million 
pounds, Cargill will still think that the material is in an early 
stage of development, but we could make a lot of money from 
that.  So, the differential is between being a company like 
Cargill, which some people have estimated is a 100-billion-
dollar company, and Tetramer, which is maybe a one-million-
dollar company.  To them, a million dollars is lost in the 
rounding in terms of revenue.  
So, we fill that range.  So, yes, for one of the products, the 
specialty plastics, we will go ahead and make it.  For the 
others that start to become high volume, we will begin to 
manufacture them, and then at some point in time, we will 
probably have someone else manufacture them and take 
about 3-4% of what they sell. 
We have had to think about this type of strategy for each of 
our products, but we  have to get out of stage two and three 
to find out what the most viable strategy is: if we want to 
manufacture in large quantities or if we want to stick with 
smaller quantities. 
Interviewer
How do you deal with competing technological interests? 




As John said, the pull from the optical area looked very 
interesting to begin with.  So, that was initially our defining 
technology, which is called PFCB technology.  It is very 
versatile stuff, and you can make a lot of different products 
out of it.
But, that area essentially crashed and burned, and we 
had those incidents that John talked about how the two 
companies went belly up and could not pay us.  Several other 
companies did the same thing.  So we decided that maybe we 
could go get a little bit more money in order to look at Steve’s 
technology a little more closely. We got an SBIR to do that, 
all the while hoping that the optical industry would come 
back, but it really did not.  
It is coming back now, but at that time we had to ask 
ourselves what other things our technology could do. 
We did not shift over into something like polyimides, or 
polycarbonates, or something totally different.  
That is when we got into fuel cells. We sat down and talked 
about fuel cells, how they are structured, and what materials 
are used in them, which got more ideas flowing. We decided 
that our technology could be used in fuel cells and would 
maybe even be better than what is out there already. 
So, we did some work on that, and wrote a proposal for it. 
We got an SBIR to start down that road, and that gave us the 
diversity and the time to say, “Okay.  If we can do fuel cells, 
what else can we do with the material?”  
Well then we tried encapsulating nanocrystals because we 
knew from work that Steve and Dave [Carroll, one of the 
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founders who subsequently left Clemson and Tetramer] had 
done that our material disperses nanocrystals very uniformly. 
That got us looking at things like quantum dots, which is 
basically a type of light source.
So, we are using the same technology, but we have found 
many different uses for it.
Interviewer
It seems like you have a very versatile technology, but is that 
unusual?  I mean, was the start of your company unusual 
compared to others? 
Earl Wagener
Let me put it to you this way.  The fact that we had four 
faculty members and me with the industrial background 
really helped. I knew where value was, but I was not sure if 
the material would work or not.  
The luck came when we actually ran the experiments, and 
the material started dispersing things extremely well. So, 
you make your own luck.  I mean, we could not just take the 
same stuff and just throw it out there. We had to modify 
it, and the stuff we are doing now is much more modified 
than what we started with, but again, it is the same polymer 
technology.
Interviewer
Did you originally begin with a business plan; did you write 
one?
Earl Wagener
Yes, we did have a business plan, but ours was much simpler 
than the business plans Caron [St. John, Director of the 
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Spiro Institute for Entrepreneurial Leadership] writes and 
the ones you will have to write.  The model I used was a four-
box business plan that I took from Dow.  
The first box included market attractiveness, both internal 
and external.  If there is enough market attractiveness, you 
assess your competitive advantage.  You have to determine 
if your competitive advantage is based on patents, costs, 
performance, etc.  This makes you ask yourself “if I sell this 
around the world, am I going to be okay?”
If you are still going strong after those two boxes, then 
you come to the box for your strategy.  How are you now 
going to take this competitive advantage and the other 
information you have and then make something of value for 
the customer?  Which customers are you going to choose and 
why?  You have to have about three or four customers to start 
off with; you really cannot sell to 50 customers, so you have 
to examine how to go about that.  
Finally, there is the financial impact part of the business 
plan.  What does your pro forma look like?  If you have this 
hockey stick curve, how do you think that you will be selling 
six times what you are making today in five years?  You have 
to re-evaluat all of these boxes while making the plan. 
Interviewer
Did you come from educational cultures that embraced 
commercialization?  How is that relative to Clemson’s culture 




Now, Clemson wants to be much more entrepreneurial than 
it has ever been in the past, and it is trying to do this by 
hiring knowledgeable entrepreneurs like Bill [Gartner].  
However, the Clemson of five or ten years ago absolutely did 
not encourage entrepreneurial activity.  They threw  stuff out 
here and there and granted a few patents, but the faculty was 
certainly not rewarded for trying to become capitalists of any 
type.  Doing so was viewed as negative.
I hope that what we are doing with this company, though, 
will give back to Clemson.  My Clemson roots go very deep 
because when my father died, my mother had to raise three 
boys all by herself. So, the town of Clemson ended up raising 
us a bit, too, because she barely made enough money on her 
own.
The town and the university gave us a tremendous kick 
forward, and all three of us wound up with PhDs somehow. 
We are giving back right now through this company, and 
I hope that what we are doing can become an example for 
others. Clemson’s entrepreneurial activity could be better, 
but it is a tough road to hoe.
I hope that there are more people who will stand up and 
encourage others to try this sort of thing and let them know 
that there is help out there to do it. People like Caron St. 
John, Dave Bodde, and Bill are working on the system to try 
and make it better.  
The younger faculty, these 26- and 28-year olds, who are 
coming in now are asking, “What can I do?  Can I do 
something?  Can I start a business?” because that is the 
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paradigm in other universities, which tell their faculty to go 
ahead and try such ventures.
Steve Foulger
Well, when we all arrived, Dennis, John, and I, we really 
did not come from this type of culture, per se.  It was a 
personality trait or dysfunction that we all have that made us 
come together.
We have this kind of commercialist attitude, but I did 
not initially think it would be of any use at Clemson. I 
honestly thought that Clemson was a village university 
where research was a hobby and that there was no aspect for 
commercialization. When I first got here, I did not think I 
would stay longer than a year, but I was proven wrong.
I got caught in the telecom crash in 1999 when I came on 
board, and it was a rough road to do anything with the 
company. In fact, I pretty much stayed outside of active work 
with the company early on. I got smacked a number of times 
from the college for being too active in terms of patenting 
things. I had a number of patents coming in, and I was still 
patenting, but I really got nailed at the Dean-level for a lot of 
the interactions I had with the company, and I was basically 
told to back off, even though I was within the letter of the 
law.  
So, I stepped back at that time, but the culture has changed 
quite a bit since then. However, at one point, we had a 
number of really interesting comments about how running a 
company as a university professor is sort of a grey area, even 
though it is perfectly legal.
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For the university, it sounds great when they are having 
news meetings or talking to administrators about what the 
university is doing for startups, but behind closed doors, they 
are looking at you and saying, “Why are you making money?” 
or “Why do you have these commercial interests?” They 
pretty much said that because we were professors, we should 
not being doing that kind of work. 
Interviewer
When you are trying to develop new things are you 
motivated by your scientific curiosity or by your 
entrepreneurial goals?
Steven Foulger
It has changed since then, but it was rough at first.  
Earl Wagener
A good friend of mine went to Purdue in 1994, and I like 
to compare them with Clemson because Purdue is 100 
miles from Indianapolis and 100 miles from Chicago. They 
are pretty much in the middle of nowhere like us, but they 
have much more support for commercial interests because 
they were able to align the governor, the president of the 
university, and the tech transfer office.  
They now have 105 companies in their little “village,” which 
are generating a huge number of jobs, and they realized that 
allowing such businesses is a good deal because they are the 
source of roughly 18 % of the grants that the faculty get.
Interviewer
You talked about your competitive advantage and how you 
compete resource-wise with bigger companies.  Do you have 
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a certain process that sets you apart from your competitors, 
or is it the material?
Earl Wagener
It is the material that sets us apart because its molecular 
architecture is better suited to do certain jobs than other 
materials that are currently out there.  For example, it 
is better at generating electricity in a fuel cell than the 
competitors’ materials.
Steve Foulger
Well, most of us are extremely aggressive people.  Yes, we are 
technically trained, and all of us did extremely well in school 
and moved very quickly.  
We are not the introvert types of people, and it was just our 
personality traits that really made us come together. We all 
had very similar personalities and thus similar goals.
Interviewer
In expanding the company are you trying to use the same 
products and use them in more ways, or are you trying to 
improve the product?  For example, if someone else comes 
out with something that is better than your product, are you 
working on being able to make up for that or develop things 
that are better than your competitors’ products?
Earl Wagener
Both. Whenever you are selling something, in most cases you 
will have a three bottle approach. I will use a commercial 
example of shampoo ingredients, which I dealt with at 
Stepan.  Let us say that L’Oreal currently has a shampoo 
product (bottle #1), but Procter and Gamble also has a 
shampoo (bottle #2) that has better performance  than 
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L’Oreal’s, putting L’Oreal at a commercial disadvantage. 
L’Oreal would come to us at Stepan and say “if you 
will develop a superior performing shampoo (bottle #3) 
to Procter’s (bottle #2), we will agree to buy all of our 
ingredients from Stepan.  
Our job then was to analyze bottles #1 and #2 and come up 
with bottle #3, which would outperform both. In some cases 
if bottle #3 just equaled Procter’s bottle #2 but was lower 
cost, we got the business. 
In essence, commercializing new technology is making bottle 
#3 products. And then you basically put technology together 
and try to improve it. In these situations, communication 
with the customer is the most important thing because they 
have to tell you what their pain points are. They always want 
you to lower your costs, but in the game we play, we have 
to consider both performance and cost.  Because our cost 
is large compared to other materials, there is no way that 
we can compete with polycarbonates in terms of just cost. 
Polycarbonates are maybe $2.00 per kilo, and our material 
is $10,000 per kilo, so we clearly have to have superior 
performance.  
We are also inventing and innovating new materials. We 
keep investigating what else we can do with the same 
material. The way we do that is by contacting companies and 
telling them that we think our product can meet their needs, 
just like we did with GM.  Right now we are going through 
that process in the area of coating glass fibers.  
Interviewer
Do you have a marketing department?
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Earl Wagener
No, not yet, but we will need one sometime.  We cannot 
afford marketing right now.  Until we have the money to pay 
someone a salary, we will just have to do some of the non-
technology-related stuff, like marketing ourselves. In terms 
of the marketing side, our faculty owners do an excellent job 
because this is a highly technical content product. When 
they go out and give fundamental academic seminars, they 
are essentially selling our technical competitive advantages. 
Since they know this technology well, they are very successful 
at selling it. It is really a win/win situation because they get 
recognition and grants for doing something really unusual, 
which then makes their product more sellable.
Interviewer
What’s your miss rate, and how does that impact your future 
projects?  
Earl Wagener
Well, in the optical area our miss rate was very high to begin 
with.  We sent a lot of samples out, but people did not call 
us back, or we had to have people who could manipulate the 
material in particular ways that we could not do ourselves. 
So, we had to send it out to them and have them do it, but 
they did not always do the right thing, so there were a lot of 
misses there. 
Early on our miss rate was probably around 80%, but now, 
I would say that we have a miss rate of 20-25% percent.  We 
are hitting pretty well right now.
